-- MediSwitch Drug Interactions Import (Part 110/112)
INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(7626, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(7332, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(6455, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(17761, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(6438, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(6449, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(6448, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(6453, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(18189, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(20787, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(1667, 'drug_class', 'N/A', 'severe', 'Interactions Drug Interactions ACE-Inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When indomethacin extended-release capsules are administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin extended-release capsules is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of indomethacin and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that indomethacin extended-release capsules can', 'DailyMed'),
(5764, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(29282, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18557, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4608, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(22480, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4527, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(5556, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23644, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(9557, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18763, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18553, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(22481, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4399, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18556, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18568, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23541, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23544, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4400, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(33274, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(22591, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18290, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(13591, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23540, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23549, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(3131, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18569, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(30192, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(14537, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18572, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(15693, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4395, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18564, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18567, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(5719, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(31061, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4675, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(11656, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23547, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(1561, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(8810, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4404, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18570, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(27531, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23543, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18560, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4408, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(5551, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18563, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(8809, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18571, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(14536, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18552, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(25432, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(24329, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18573, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4607, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23550, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(3455, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(30014, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23545, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(9472, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18555, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(30571, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(25431, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(32893, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(7315, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18574, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(22026, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(8808, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(1663, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(31062, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18562, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(3711, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(24261, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(13590, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4403, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(18558, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(8812, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(10325, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(30509, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(4166, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(22590, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(6973, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(30193, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(24260, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(32814, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(27532, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(23552, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed'),
(28258, 'iron', 'N/A', 'minor', 'Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole ) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23261, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(33251, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(8577, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(23262, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(24265, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(23259, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(23200, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(22397, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(8543, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(23222, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(27732, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(296, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(23260, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. Aspirin When naproxen is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and aspirin is not generally recommended because of the potential of increased adverse effects. Furosemide Clinical studies, as well as post marketing observations, have shown that naproxen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attribut', 'DailyMed'),
(17569, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(22970, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(32055, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(24589, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(19572, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(32336, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(5710, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(3069, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(2682, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(15671, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(23763, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(30394, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(19408, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(26700, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(2664, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(6407, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(2815, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(18231, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(29795, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(30393, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(29294, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(24628, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(159, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(16250, 'drug_class', 'N/A', 'minor', 'Drug Interactions: Do not eat or drink dairy products within one hour of fluoride administration. Incompatibility of fluoride with dairy foods has been reported due to formation of calcium fluoride which is poorly absorbed.', 'DailyMed'),
(28990, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(25113, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(32236, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28985, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28989, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28992, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28982, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(7255, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(25778, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28981, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(25112, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28995, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(33836, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28986, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(18514, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(31180, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28988, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(29007, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(25111, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(29144, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28983, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(7519, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28987, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(25115, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(29005, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(29006, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28605, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(25114, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(28984, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(29296, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(10684, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(26260, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(33837, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(26261, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(26353, 'glycerin', 'N/A', 'minor', 'These effects were not observed when vardenafil 20 mg was taken 24 hours before the nitroglycerin (NTG).', 'DailyMed'),
(13766, 'drug_class', 'N/A', 'minor', 'Drug Interactions The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital. The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs. Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride. If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.', 'DailyMed'),
(18313, 'drug_class', 'N/A', 'minor', 'Drug Interactions The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital. The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs. Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride. If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.', 'DailyMed'),
(17004, 'drug_class', 'N/A', 'minor', 'Drug Interactions The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital. The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs. Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride. If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.', 'DailyMed'),
(4180, 'drug_class', 'N/A', 'minor', 'Drug Interactions The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital. The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs. Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride. If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.', 'DailyMed'),
(17003, 'drug_class', 'N/A', 'minor', 'Drug Interactions The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital. The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs. Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride. If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.', 'DailyMed'),
(4177, 'drug_class', 'N/A', 'minor', 'Drug Interactions The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital. The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs. Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride. If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.', 'DailyMed'),
(6706, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(6706, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(6706, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(6706, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(6706, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(6706, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(6706, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(6706, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(6702, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(6702, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(6702, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(6702, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(6702, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(19852, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(19852, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(19852, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(19852, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(19852, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(19852, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(19852, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(19852, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(21136, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(21136, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(21136, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(21136, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(21136, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(19853, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(19853, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(19853, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(19853, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(19853, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(5531, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(5531, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(5531, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(5531, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(5531, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(5531, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(5531, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(5531, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(8020, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(8020, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(8020, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(8020, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(8020, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(8020, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(8020, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(8020, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(19806, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(19806, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(19806, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(19806, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(19806, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(5530, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(5530, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(5530, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(5530, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(5530, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(3965, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(3965, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(3965, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(3965, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(3965, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(3965, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(3965, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(3965, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(33401, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(33401, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(33401, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(33401, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(33401, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(33401, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(33401, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(33401, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(2104, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(2104, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(2104, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(2104, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(2104, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(31287, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(31287, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(31287, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(31287, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(31287, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(6699, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(6699, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(6699, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(6699, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(6699, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(21135, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(21135, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(21135, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(21135, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(21135, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(21135, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(21135, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(21135, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(19818, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(19818, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(19818, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(19818, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(19818, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(19854, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(19854, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(19854, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(19854, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(19854, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(19817, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(19817, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(19817, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(19817, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(19817, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(21130, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(21130, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(21130, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(21130, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(21130, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(21130, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(21130, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(21130, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(6703, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(6703, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(6703, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(6703, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(6703, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(21138, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(21138, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(21138, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(21138, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(21138, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(21131, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(21131, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(21131, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(21131, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(21131, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(21131, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(21131, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(21131, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(2173, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(2173, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(2173, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(2173, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(2173, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(2173, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(2173, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(2173, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(21141, 'sitagliptin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Digoxin There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.', 'DailyMed'),
(21141, 'colesevelam hydrochloride', 'N/A', 'minor', 'Table 4 Drugs Tested in In Vitro Binding or In Vivo Drug Interaction Testing or With Post-Marketing Reports Drugs with a known interaction with colesevelam:Decrease in exposure of coadministered drug cyclosporinec, glimepiridea, glipizidea, glyburidea,levothyroxinea, olmesartan medoxomila, and oralcontraceptives containing ethinyl estradiol andnorethindronea Drugs with a known interaction with colesevelam:Increase in exposure of coadministered drug metformin extended release (ER)d Drug(s) with postmarketing reports consistent withpotential drug-drug interactions whencoadministered with WELCHOL phenytoina, warfarinb Drugs that do not interact with colesevelam basedon in vitro or in vivo testing aspirin, atenolol, cephalexin, ciprofloxacin,digoxin, enalapril, fenofibrate, lovastatin,metformi', 'DailyMed'),
(21141, 'lomitapide mesylate', 'N/A', 'minor', 'Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates.', 'DailyMed'),
(21141, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]', 'DailyMed'),
(21141, 'dapagliflozin', 'N/A', 'minor', 'No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg   Pioglitazone (45 mg) 50 mg   Sitagliptin (100 mg) 20 mg   Glimepiride (4 mg) 20 mg   Voglibose (0.2 mg three times daily) 10 mg   Other Medications Hydrochlorothiazide (25 mg) 50 mg   Bumetanide (1 mg) 10 mg once dailyfor 7 days   Valsartan (320 mg) 20 mg 12%[3%, 20%]  Simvastatin (40 mg) 20 mg   Anti-infective Agent Rifampin (600 mg once daily for 6 days) 10 mg 7%[22%, 11%] 22%[27%, 17%] Nonsteroidal Anti-inflammatory Agent Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) 10 mg 13%[3%, 24%] 51%[44%, 58%]  = no change (geometric mean ratio of test: reference within 0.80 to 1.25);  or  = parameter was lower or higher, r', 'DailyMed'),
(21141, 'sitagliptin and metformin hydrochloride', 'N/A', 'major', '7 DRUG INTERACTIONS Table 4 presents clinically significant drug interactions with sitagliptin and metformin hydrochloride extended-release tablets: Table 4 Clinically Significant Drug Interactions with Sitagliptin and Metformin Hydrochloride Extended-Release Tablets Carbonic Anhydrase Inhibitors Clinical Impact: Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with sitagliptin and metformin hydrochloride extended-release tablets may increase the risk for lactic acidosis. Intervention: Consider the benefits and risks of concomitant use with sitagliptin and metformin hydrochloride extended-release tablets.', 'DailyMed'),
(21141, 'ferric citrate', 'N/A', 'minor', '7 DRUG INTERACTIONS Table 2: Oral drugs that can be administered concomitantly with Auryxia Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Auryxia and meals Dosing Recommendations Doxycycline Take at least 1 hour before Auryxia Ciprofloxacin Take at least 2 hours before or after Auryxia Oral medications not listed in Table 2 There are no empirical data on avoiding drug interactions between Auryxia and most concomitant oral drugs.', 'DailyMed'),
(21141, 'vadadustat', 'N/A', 'minor', 'Examples* cefaclor, ceftizoxime, famotidine, furosemide, oseltamivir carboxylate, penicillin G, sitagliptin *These examples are not a comprehensive list of all possible drugs that may fit this category.', 'DailyMed'),
(1260, 'drug_class', 'N/A', 'minor', 'Drug interactions The central nervous system depressant effects of baclofen may be additive to those of alcohol and other CNS depressants.', 'DailyMed'),
(8502, 'drug_class', 'N/A', 'minor', 'Drug interactions The central nervous system depressant effects of baclofen may be additive to those of alcohol and other CNS depressants.', 'DailyMed'),
(14175, 'drug_class', 'N/A', 'minor', 'Drug interactions The central nervous system depressant effects of baclofen may be additive to those of alcohol and other CNS depressants.', 'DailyMed'),
(31398, 'drug_class', 'N/A', 'minor', 'Drug interactions The central nervous system depressant effects of baclofen may be additive to those of alcohol and other CNS depressants.', 'DailyMed'),
(1257, 'drug_class', 'N/A', 'minor', 'Drug interactions The central nervous system depressant effects of baclofen may be additive to those of alcohol and other CNS depressants.', 'DailyMed'),
(8501, 'drug_class', 'N/A', 'minor', 'Drug interactions The central nervous system depressant effects of baclofen may be additive to those of alcohol and other CNS depressants.', 'DailyMed'),
(8157, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions With NAYZILAM 7.1 CYP3A4 Inhibitors Clinical Impact: Concomitant use of CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. Intervention: Avoid co-administration of NAYZILAM with moderate or strong CYP3A4 inhibitors. NAYZILAM should be used with caution when co-administered with mild CYP3A4 inhibitors. Examples: Moderate CYP3A4 inhibitors: erythromycin, diltiazem, verapamilStrong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin 7.2 Opioids Clinical Impact: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines inter', 'DailyMed'),
(30919, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions With NAYZILAM 7.1 CYP3A4 Inhibitors Clinical Impact: Concomitant use of CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. Intervention: Avoid co-administration of NAYZILAM with moderate or strong CYP3A4 inhibitors. NAYZILAM should be used with caution when co-administered with mild CYP3A4 inhibitors. Examples: Moderate CYP3A4 inhibitors: erythromycin, diltiazem, verapamilStrong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin 7.2 Opioids Clinical Impact: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines inter', 'DailyMed'),
(30918, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions With NAYZILAM 7.1 CYP3A4 Inhibitors Clinical Impact: Concomitant use of CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. Intervention: Avoid co-administration of NAYZILAM with moderate or strong CYP3A4 inhibitors. NAYZILAM should be used with caution when co-administered with mild CYP3A4 inhibitors. Examples: Moderate CYP3A4 inhibitors: erythromycin, diltiazem, verapamilStrong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin 7.2 Opioids Clinical Impact: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines inter', 'DailyMed'),
(3846, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions With NAYZILAM 7.1 CYP3A4 Inhibitors Clinical Impact: Concomitant use of CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. Intervention: Avoid co-administration of NAYZILAM with moderate or strong CYP3A4 inhibitors. NAYZILAM should be used with caution when co-administered with mild CYP3A4 inhibitors. Examples: Moderate CYP3A4 inhibitors: erythromycin, diltiazem, verapamilStrong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin 7.2 Opioids Clinical Impact: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines inter', 'DailyMed'),
(8158, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions With NAYZILAM 7.1 CYP3A4 Inhibitors Clinical Impact: Concomitant use of CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. Intervention: Avoid co-administration of NAYZILAM with moderate or strong CYP3A4 inhibitors. NAYZILAM should be used with caution when co-administered with mild CYP3A4 inhibitors. Examples: Moderate CYP3A4 inhibitors: erythromycin, diltiazem, verapamilStrong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin 7.2 Opioids Clinical Impact: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines inter', 'DailyMed'),
(22734, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions With NAYZILAM 7.1 CYP3A4 Inhibitors Clinical Impact: Concomitant use of CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. Intervention: Avoid co-administration of NAYZILAM with moderate or strong CYP3A4 inhibitors. NAYZILAM should be used with caution when co-administered with mild CYP3A4 inhibitors. Examples: Moderate CYP3A4 inhibitors: erythromycin, diltiazem, verapamilStrong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin 7.2 Opioids Clinical Impact: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines inter', 'DailyMed'),
(3847, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Table 3: Clinically Significant Drug Interactions With NAYZILAM 7.1 CYP3A4 Inhibitors Clinical Impact: Concomitant use of CYP3A4 inhibitors may result in prolonged sedation because of a decrease in plasma clearance of midazolam. Intervention: Avoid co-administration of NAYZILAM with moderate or strong CYP3A4 inhibitors. NAYZILAM should be used with caution when co-administered with mild CYP3A4 inhibitors. Examples: Moderate CYP3A4 inhibitors: erythromycin, diltiazem, verapamilStrong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin 7.2 Opioids Clinical Impact: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines inter', 'DailyMed'),
(29020, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(24700, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(24699, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(9729, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(29029, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(25746, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(12106, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(24780, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(28435, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(11607, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(9007, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(12107, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(25745, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(31554, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(11608, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(25747, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Pentoxifylline extended-release Tablet with and without anticoagulants or platelet aggregation inhibitors. Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examination for bleeding including hematocrit and/or hemoglobin. Concomitant administration of Pentoxifylline extended-release Tablet and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. Such patients should be closely monitored for signs of toxici', 'DailyMed'),
(24601, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(24601, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(24601, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(10367, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(10367, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(10367, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(33385, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(33385, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33385, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(24602, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(24602, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(24602, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(9669, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(9669, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(9669, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(24603, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(24603, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(24603, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(33383, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(33383, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33383, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(24598, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(24598, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(24598, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(24597, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(24597, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(24597, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(10366, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(10366, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(10366, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(33384, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(33384, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(33384, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(9657, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(9657, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(9657, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(17265, 'tramadol', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(17265, 'iron', 'N/A', 'minor', 'Serotonergic Drugs If concomitant use of Paroxetine Capsules with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St.', 'DailyMed'),
(17265, 'venlafaxine', 'N/A', 'minor', 'Examples propafenone, flecainide, atomoxetine, desipramine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine, venlafaxine, risperidone.', 'DailyMed'),
(22081, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(26997, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(20792, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(21168, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(19803, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27019, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(12907, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27028, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27017, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(22774, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(14800, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27024, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(21169, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(687, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(687, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(7379, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(15960, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29986, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(29986, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27014, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(13763, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(22773, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(33767, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(21875, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(22772, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(22772, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27020, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(30739, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(17864, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(14073, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(14073, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(10481, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(10481, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29908, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29040, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(21896, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29907, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(28971, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(15120, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27025, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29987, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(29987, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29988, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(11430, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27021, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(27021, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27026, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29985, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(29985, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29038, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27018, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(20790, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(2171, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27013, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(19804, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(17865, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27012, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(27012, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29202, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29039, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(14074, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(14074, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(10489, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(26998, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(2172, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(22079, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(22079, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27011, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(27011, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(21895, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(13332, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(3084, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(3084, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27015, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(13182, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(27027, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(29203, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(369, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(10487, 'drug_class', 'N/A', 'major', 'Drug Interactions CYP3A4 Interactions Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4. Potent inhibitors of CYP3A4 (below) increase the risk of myopathy by reducing the elimination of simvastatin.See WARNINGS, Myopathy/Rhabdomyolysis, and CLINICAL PHARMACOLOGY, Pharmacokinetics. Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Large quantities of grapefruit juice (>1 quart daily) Interactions with lipid-lowering drugs that can cause myopathy when given alone See WARNINGS, Myopathy/Rhabdomyolysis.The risk of myopathy is increased by gemfibrozil (see DOSAGE AND ADMINISTRATION) and to a lesser extent by other fi', 'DailyMed'),
(10487, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(13855, 'amlodipine', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.3, 4, 5.1, 7.1, 7.2, 7.3, 7.4) Interacting Agents Prescribing Recommendations Itraconazole, ketoconazole, Posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine,danazol Contraindicated with simvastatin Verapamil, diltiazem Do not exceed 10 mg simvastatin daily Amiodarone, amlodipine, ranolazine Do not exceed 20 mg simvastatin daily Grapefruit juice Avoid large quantities of grapefruit juice (>1 quart daily) Other Lipid-lowering Medications: Use with other fibrate products or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skeletal muscle effects. 7.3 Amiodarone, Ranolazine, or Calcium Channel Blockers ', 'DailyMed'),
(4635, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(5363, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(814, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(810, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(26877, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(24715, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(4633, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(4636, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(5362, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(4496, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(14256, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(24718, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(10381, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(11168, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(11825, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(2932, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(24717, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(2432, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(812, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(6825, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(4632, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(18355, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(24714, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(6823, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(14254, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(817, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(19605, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(28456, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(18356, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(19600, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(18784, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(18792, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(21164, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(14259, 'drug_class', 'N/A', 'major', 'Drug interactions No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.', 'DailyMed'),
(12681, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS No drug interactions have been identified based on the limited available data on the emergency use of LAGEVRIO authorized under this EUA. No clinical drug-drug interaction trials of LAGEVRIO with concomitant medications, including other treatments for mild-to-moderate COVID-19, have been conducted [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32310, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS No drug interactions have been identified based on the limited available data on the emergency use of LAGEVRIO authorized under this EUA. No clinical drug-drug interaction trials of LAGEVRIO with concomitant medications, including other treatments for mild-to-moderate COVID-19, have been conducted [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(11573, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS No drug interactions have been identified based on the limited available data on the emergency use of LAGEVRIO authorized under this EUA. No clinical drug-drug interaction trials of LAGEVRIO with concomitant medications, including other treatments for mild-to-moderate COVID-19, have been conducted [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32218, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS No drug interactions have been identified based on the limited available data on the emergency use of LAGEVRIO authorized under this EUA. No clinical drug-drug interaction trials of LAGEVRIO with concomitant medications, including other treatments for mild-to-moderate COVID-19, have been conducted [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(32304, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS No drug interactions have been identified based on the limited available data on the emergency use of LAGEVRIO authorized under this EUA. No clinical drug-drug interaction trials of LAGEVRIO with concomitant medications, including other treatments for mild-to-moderate COVID-19, have been conducted [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(19508, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS No drug interactions have been identified based on the limited available data on the emergency use of LAGEVRIO authorized under this EUA. No clinical drug-drug interaction trials of LAGEVRIO with concomitant medications, including other treatments for mild-to-moderate COVID-19, have been conducted [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(8041, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS No drug interactions have been identified based on the limited available data on the emergency use of LAGEVRIO authorized under this EUA. No clinical drug-drug interaction trials of LAGEVRIO with concomitant medications, including other treatments for mild-to-moderate COVID-19, have been conducted [see Clinical Pharmacology (12.3)].', 'DailyMed'),
(6675, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(6675, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(6675, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(6675, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(6667, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(6667, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(6667, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(6667, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(6678, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(6678, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(6678, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(6678, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(21067, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(21067, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(21067, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(21067, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(6669, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(6669, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(6669, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(6669, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(14419, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(14419, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(14419, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(14419, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(27421, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(27421, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(27421, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(27421, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(28046, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(28046, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(28046, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(28046, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(959, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(959, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(959, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(959, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(21070, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(21070, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(21070, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(21070, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(6676, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(6676, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(6676, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(6676, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(6670, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(6670, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(6670, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(6670, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(21063, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(21063, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(21063, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(21063, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(19476, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(19476, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(19476, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(19476, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(21065, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(21065, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(21065, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(21065, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(6674, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(6674, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(6674, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(6674, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(10830, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(10830, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(10830, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(10830, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(19475, 'drug_class', 'N/A', 'contraindicated', 'Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, and, in subjects with varying degrees of renal or hepatic impairment, colchicine, fesoterodine, telithromycin and solifenacin. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole, may increase or pro', 'DailyMed'),
(19475, 'iron', 'N/A', 'minor', 'Antipsychotics, Anxiolytics and Hypnotics lurasidone, oral midazolam, pimozide, triazolam alprazolam, aripiprazole, buspirone, diazepam, haloperidol, midazolam IV, perospirone, quetiapine, ramelteon, risperidone Midazolam, triazolam: Coadministration of itraconazole and oral midazolam, or triazolam may cause several-fold increases in plasma concentrations of these drugs.', 'DailyMed'),
(19475, 'venlafaxine', 'N/A', 'moderate', 'SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions.', 'DailyMed'),
(19475, 'silodosin', 'N/A', 'minor', 'Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers AlfuzosinSilodosinTamsulosin Not recommended during and 2 weeks after itraconazole treatment.', 'DailyMed'),
(29607, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(29607, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29607, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32789, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(32789, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32789, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21849, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(21849, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21849, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6221, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(6221, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(6221, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21851, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(21851, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21851, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7330, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(7330, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7330, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24391, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(24391, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24391, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17141, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(17141, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17141, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25918, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(25918, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(25918, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14747, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(14747, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14747, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7329, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(7329, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(7329, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17142, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(17142, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(17142, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29354, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(29354, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29354, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21121, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(21121, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21121, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13118, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(13118, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13118, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30068, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(30068, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(30068, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29606, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(29606, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29606, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14745, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(14745, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14745, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21122, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(21122, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21122, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14879, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(14879, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14879, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1162, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(1162, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(1162, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21848, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(21848, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21848, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29608, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(29608, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(29608, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24390, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(24390, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(24390, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(12965, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(12965, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(12965, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14748, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(14748, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(14748, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32064, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(32064, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(32064, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13322, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(13322, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(13322, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21850, 'drug_class', 'N/A', 'moderate', 'Drug Interactions (see also CLINICAL PHARMACOLOGY, Drug-Drug Interactions) Monoamine Oxidase Inhibition Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents: Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with ', 'DailyMed'),
(21850, 'vitamin e', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(21850, 'vitamin c', 'N/A', 'minor', 'Antioxidants The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. On Days 29, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC0 of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E.', 'DailyMed'),
(2994, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(18577, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(17919, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(3762, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(17916, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(3521, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(28854, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(3522, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(24409, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(24407, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(17918, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(31540, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(11970, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(17403, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(24408, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(17404, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(11969, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Co-administration with other anticholinergic drugs may increase the frequency and/or severity of anticholinergic-like effects. (7) Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (7) The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may a', 'DailyMed'),
(27747, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(6741, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(26315, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(18583, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(1325, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(26316, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(28510, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(16101, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(3565, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(21555, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(3153, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(16102, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(2803, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(16899, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(6621, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(26312, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(26321, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(13473, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(3146, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(31762, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(5634, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(2513, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(18452, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(21912, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(19426, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(13008, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(15052, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(12994, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(19425, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(17172, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(6984, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(6604, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(6861, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(3147, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(6983, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(24690, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(32934, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(12117, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(21205, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(7068, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(2804, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(2515, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(5156, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(16099, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(7467, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(15265, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(30048, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(30993, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(24691, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(18582, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(4413, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(10019, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(6982, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(3151, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(6844, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(16100, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(3150, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(32690, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(1376, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(22681, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(4609, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(16261, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(13009, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(26318, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(12815, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(17173, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(27748, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(4414, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(30994, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(9121, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(31839, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(6599, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(13527, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(19424, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(30992, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(26311, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(10021, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(27480, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(12118, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(3152, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(13526, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(3154, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(32933, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(12992, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(16904, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(6845, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(10017, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(18451, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Cyclosporine: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 5 mg once daily. ( 2.4, 5.1, 7.1, 12.3)  Gemfibrozil: Combination should be avoided. If used together, limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.2)  Atazanavir/ritonavir, lopinavir/ritonavir, or simeprevir: Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily. ( 2.4, 5.1, 7.3, 12.3)  Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting rosuvastatin tablets. Monitor INR frequently until stable upon initiation or alteration of rosuvastatin therapy. ( 5.3, 7.4)  Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (1 g/day) of niacin increases the risk of adverse skel', 'DailyMed'),
(22509, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(8258, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(22504, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(7832, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(22864, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(8109, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(8373, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(7917, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(7918, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(8110, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(7833, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(786, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(8265, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(8263, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(22511, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(788, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(8107, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(7913, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(7912, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(22443, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(7905, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(790, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(789, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(14435, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(8111, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(7909, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(7906, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(22878, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(22879, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(8372, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(14230, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(22866, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(7835, 'drug_class', 'N/A', 'severe', 'Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. Aspirin When meloxicam is administered with aspirin (1000 mg TID) to healthy volunteers, it tended to increase the AUC (10%) and Cmax (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other NSAIDs concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.Concomitant administration of low-dose aspirin with meloxicam may result in an increased rate of GI ulceration or other complications, compared to use of meloxicam alone. Meloxicam is not a s', 'DailyMed'),
(9241, 'metformin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(24093, 'metformin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(24088, 'metformin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(9238, 'metformin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(24092, 'metformin', 'N/A', 'minor', '7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast.', 'DailyMed'),
(28950, 'drug_class', 'N/A', 'major', 'DRUG INTERACTIONS SECTION No clinically significant drug-drug or drug-food interactions with valacyclovir hydrochloride are known [see CLINICAL PHARMACOLOGY (12.3)].', 'DailyMed'),
(28952, 'drug_class', 'N/A', 'major', 'DRUG INTERACTIONS SECTION No clinically significant drug-drug or drug-food interactions with valacyclovir hydrochloride are known [see CLINICAL PHARMACOLOGY (12.3)].', 'DailyMed'),
(28953, 'drug_class', 'N/A', 'major', 'DRUG INTERACTIONS SECTION No clinically significant drug-drug or drug-food interactions with valacyclovir hydrochloride are known [see CLINICAL PHARMACOLOGY (12.3)].', 'DailyMed'),
(29405, 'drug_class', 'N/A', 'major', 'DRUG INTERACTIONS SECTION No clinically significant drug-drug or drug-food interactions with valacyclovir hydrochloride are known [see CLINICAL PHARMACOLOGY (12.3)].', 'DailyMed'),
(20428, 'drug_class', 'N/A', 'major', 'DRUG INTERACTIONS SECTION No clinically significant drug-drug or drug-food interactions with valacyclovir hydrochloride are known [see CLINICAL PHARMACOLOGY (12.3)].', 'DailyMed'),
(28951, 'drug_class', 'N/A', 'major', 'DRUG INTERACTIONS SECTION No clinically significant drug-drug or drug-food interactions with valacyclovir hydrochloride are known [see CLINICAL PHARMACOLOGY (12.3)].', 'DailyMed'),
(32049, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Rifampin:Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2.6, 7.1) Carbamazepine:Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7.2) Phenytoin:Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7.3) Levetiracetam:BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7.4) 7.1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction [see Clinical Pharmacology (12.3)] . Prescribers should increase the BRIVIACT dose by up to 1', 'DailyMed'),
(2948, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Rifampin:Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2.6, 7.1) Carbamazepine:Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7.2) Phenytoin:Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7.3) Levetiracetam:BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7.4) 7.1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction [see Clinical Pharmacology (12.3)] . Prescribers should increase the BRIVIACT dose by up to 1', 'DailyMed'),
(25731, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Rifampin:Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2.6, 7.1) Carbamazepine:Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7.2) Phenytoin:Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7.3) Levetiracetam:BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7.4) 7.1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction [see Clinical Pharmacology (12.3)] . Prescribers should increase the BRIVIACT dose by up to 1', 'DailyMed'),
(30851, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Rifampin:Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2.6, 7.1) Carbamazepine:Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7.2) Phenytoin:Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7.3) Levetiracetam:BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7.4) 7.1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction [see Clinical Pharmacology (12.3)] . Prescribers should increase the BRIVIACT dose by up to 1', 'DailyMed'),
(32050, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Rifampin:Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2.6, 7.1) Carbamazepine:Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7.2) Phenytoin:Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7.3) Levetiracetam:BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7.4) 7.1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction [see Clinical Pharmacology (12.3)] . Prescribers should increase the BRIVIACT dose by up to 1', 'DailyMed'),
(7861, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Rifampin:Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2.6, 7.1) Carbamazepine:Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7.2) Phenytoin:Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7.3) Levetiracetam:BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7.4) 7.1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction [see Clinical Pharmacology (12.3)] . Prescribers should increase the BRIVIACT dose by up to 1', 'DailyMed'),
(10838, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Rifampin:Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2.6, 7.1) Carbamazepine:Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7.2) Phenytoin:Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7.3) Levetiracetam:BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7.4) 7.1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction [see Clinical Pharmacology (12.3)] . Prescribers should increase the BRIVIACT dose by up to 1', 'DailyMed'),
(8212, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(8212, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(8212, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(1012, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(1012, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(1012, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(684, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(684, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(684, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(29717, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(29717, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(29717, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(28531, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(28531, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(28531, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(12208, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(12208, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(12208, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(8210, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(8210, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(8210, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(28107, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(28107, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(28107, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(28106, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(28106, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(28106, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(28482, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(28482, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(28482, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(11348, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(11348, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(11348, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(1004, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(1004, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(1004, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(28481, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(28481, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(28481, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(33792, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(33792, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(33792, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(16323, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(16323, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(16323, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(28745, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(28745, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(28745, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(11761, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(11761, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(11761, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(1738, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(1738, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(1738, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(28108, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(28108, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(28108, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(28044, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(28044, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(28044, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(28105, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(28105, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(28105, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(4682, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(4682, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(4682, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(12209, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(12209, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(12209, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(25547, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(25547, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(25547, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(11354, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(11354, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(11354, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(28102, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(28102, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(28102, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(11909, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(11909, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(11909, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(11349, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(11349, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(11349, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(4681, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(4681, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(4681, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(25546, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(25546, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(25546, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(14071, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(14071, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(14071, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(19894, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(19894, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(19894, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(8646, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(8646, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(8646, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(2580, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(2580, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(2580, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(4002, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (See PRECAUTIONS, Drug Interactions , Table II ).', 'DailyMed'),
(4002, 'caffeine', 'N/A', 'minor', 'Albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without sulbactam methylprednisolone metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin prednisone, prednisolone enflurane ranitidine famotidine rifabutin felodipine roxithromycin finasteride sorbitol (purgative doses do not inhibit hydrocortisone theophylline absorption) isoflurane sucralfate isoniazid terbutaline, systemic isradipine terfenadine influenza vaccine tetracycline ketoconazole tocainide lomefloxacin', 'DailyMed'),
(4002, 'dyphylline', 'N/A', 'minor', 'Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays.', 'DailyMed'),
(806, 'drug_class', 'N/A', 'minor', 'Drug Interactions Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.', 'DailyMed'),
(12227, 'drug_class', 'N/A', 'minor', 'Drug Interactions Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.', 'DailyMed'),
(12231, 'drug_class', 'N/A', 'minor', 'Drug Interactions Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.', 'DailyMed'),
(12232, 'drug_class', 'N/A', 'minor', 'Drug Interactions Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.', 'DailyMed'),
(24770, 'drug_class', 'N/A', 'minor', 'Drug Interactions Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.', 'DailyMed'),
(805, 'drug_class', 'N/A', 'minor', 'Drug Interactions Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.', 'DailyMed'),
(24682, 'drug_class', 'N/A', 'minor', 'Drug Interactions Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.', 'DailyMed'),
(14222, 'drug_class', 'N/A', 'minor', 'Drug Interactions Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.', 'DailyMed'),
(24681, 'drug_class', 'N/A', 'minor', 'Drug Interactions Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.', 'DailyMed'),
(15669, 'drug_class', 'N/A', 'minor', 'Drug Interactions Because of the danger involved in the simultaneous use of calcium salts and drugs of the digitalis group, a digitalized patient should not receive an intravenous injection of a calcium compound unless the indications are clearly defined. Calcium salts should not generally be mixed with carbonates, phosphates, sulfates or tartrates in parenteral admixtures.', 'DailyMed'),
(14102, 'caffeine', 'N/A', 'minor', 'Drug Interactions: Oral maintenance theophylline and other xanthine derivatives such as caffeine may abolish the coronary vasodilatation induced by intravenous dipyridamole administration.', 'DailyMed'),
(14102, 'drug_class', 'N/A', 'minor', 'Drug Interactions No pharmacokinetic drug-drug interaction studies were conducted with dipyridamole tablets USP. The following information was obtained from the literature. Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Adenosine: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. Cholinesterase Inhibitors:', 'DailyMed'),
(25193, 'caffeine', 'N/A', 'minor', 'Drug Interactions: Oral maintenance theophylline and other xanthine derivatives such as caffeine may abolish the coronary vasodilatation induced by intravenous dipyridamole administration.', 'DailyMed'),
(25193, 'drug_class', 'N/A', 'minor', 'Drug Interactions No pharmacokinetic drug-drug interaction studies were conducted with dipyridamole tablets USP. The following information was obtained from the literature. Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Adenosine: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. Cholinesterase Inhibitors:', 'DailyMed'),
(24773, 'caffeine', 'N/A', 'minor', 'Drug Interactions: Oral maintenance theophylline and other xanthine derivatives such as caffeine may abolish the coronary vasodilatation induced by intravenous dipyridamole administration.', 'DailyMed'),
(24773, 'drug_class', 'N/A', 'minor', 'Drug Interactions No pharmacokinetic drug-drug interaction studies were conducted with dipyridamole tablets USP. The following information was obtained from the literature. Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Adenosine: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. Cholinesterase Inhibitors:', 'DailyMed'),
(29075, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. ( 7.1) Strong CYP3A4 Inducers: Avoid concomitant use. (7.3) 7.1 Effects of Other Drugs on Bortezomib for injection Strong CYP3A4 Inducers Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [ see Clinical Pharmacology (12.3) ] which may decrease Bortezomib for injection efficacy. Avoid coadministration with strong CYP3A4 inducers. Strong CYP3A4 Inhibitors Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib [ see Clinical Pharmacology (12.3) ] which may increase the risk of Bortezomib for injection toxicities. Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combin', 'DailyMed'),
(24477, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. ( 7.1) Strong CYP3A4 Inducers: Avoid concomitant use. (7.3) 7.1 Effects of Other Drugs on Bortezomib for injection Strong CYP3A4 Inducers Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [ see Clinical Pharmacology (12.3) ] which may decrease Bortezomib for injection efficacy. Avoid coadministration with strong CYP3A4 inducers. Strong CYP3A4 Inhibitors Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib [ see Clinical Pharmacology (12.3) ] which may increase the risk of Bortezomib for injection toxicities. Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combin', 'DailyMed'),
(29074, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. ( 7.1) Strong CYP3A4 Inducers: Avoid concomitant use. (7.3) 7.1 Effects of Other Drugs on Bortezomib for injection Strong CYP3A4 Inducers Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [ see Clinical Pharmacology (12.3) ] which may decrease Bortezomib for injection efficacy. Avoid coadministration with strong CYP3A4 inducers. Strong CYP3A4 Inhibitors Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib [ see Clinical Pharmacology (12.3) ] which may increase the risk of Bortezomib for injection toxicities. Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combin', 'DailyMed'),
(15448, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. ( 7.1) Strong CYP3A4 Inducers: Avoid concomitant use. (7.3) 7.1 Effects of Other Drugs on Bortezomib for injection Strong CYP3A4 Inducers Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [ see Clinical Pharmacology (12.3) ] which may decrease Bortezomib for injection efficacy. Avoid coadministration with strong CYP3A4 inducers. Strong CYP3A4 Inhibitors Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib [ see Clinical Pharmacology (12.3) ] which may increase the risk of Bortezomib for injection toxicities. Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combin', 'DailyMed'),
(5164, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. ( 7.1) Strong CYP3A4 Inducers: Avoid concomitant use. (7.3) 7.1 Effects of Other Drugs on Bortezomib for injection Strong CYP3A4 Inducers Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [ see Clinical Pharmacology (12.3) ] which may decrease Bortezomib for injection efficacy. Avoid coadministration with strong CYP3A4 inducers. Strong CYP3A4 Inhibitors Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib [ see Clinical Pharmacology (12.3) ] which may increase the risk of Bortezomib for injection toxicities. Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combin', 'DailyMed'),
(22716, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22712, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(5813, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(8133, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22709, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(8128, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(20125, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(4062, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22711, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(8290, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22715, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22713, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22918, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(32932, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(8139, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(8138, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(23154, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(3289, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(5822, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(3506, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(20115, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22698, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22915, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22702, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(23171, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(8494, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(33396, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(1779, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22903, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(20110, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(8134, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(17067, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(18163, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(4070, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(25036, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(28524, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22705, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(8280, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(24704, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22880, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(23169, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(23170, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(8137, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(22719, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS Warfarin: Miconazole may enhance anticoagulant effect. Monitor prothrombin time, INR, and watch for bleeding (7.1). 7.1 Warfarin Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding. 7.2 Drugs Metabolized Through CYP 2C9 and 3A4 No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of ', 'DailyMed'),
(16331, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(26816, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(16451, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(6465, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(16581, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(20796, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(31976, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(23018, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(16332, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(26817, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(16453, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(26692, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(27487, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(27952, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(25011, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(16329, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(2710, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(2707, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(26693, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(25010, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(16583, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(16330, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(27489, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(16455, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(27488, 'drug_class', 'N/A', 'major', 'Drug Interactions :Since cilostazol is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when cilostazol is coadministered with inhibitors of CYP3A4 such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of CYP3A4 (see CLINICAL PHARMACOLOGY, Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions ). Cilostazol does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lo', 'DailyMed'),
(17702, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Opioids and Sedatives The induction dose requirements of propofol may be reduced in patients with intramuscular or intravenous premedication, particularly with opioids (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of propofol and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output. In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia. Analgesic Agents During maintenance of anesthesia or sedation, the rate of propofol administration should be adjusted according to the desir', 'DailyMed'),
(3728, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Opioids and Sedatives The induction dose requirements of propofol may be reduced in patients with intramuscular or intravenous premedication, particularly with opioids (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of propofol and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output. In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia. Analgesic Agents During maintenance of anesthesia or sedation, the rate of propofol administration should be adjusted according to the desir', 'DailyMed'),
(25765, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Opioids and Sedatives The induction dose requirements of propofol may be reduced in patients with intramuscular or intravenous premedication, particularly with opioids (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of propofol and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output. In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia. Analgesic Agents During maintenance of anesthesia or sedation, the rate of propofol administration should be adjusted according to the desir', 'DailyMed'),
(25024, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Opioids and Sedatives The induction dose requirements of propofol may be reduced in patients with intramuscular or intravenous premedication, particularly with opioids (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of propofol and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output. In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia. Analgesic Agents During maintenance of anesthesia or sedation, the rate of propofol administration should be adjusted according to the desir', 'DailyMed'),
(25766, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Opioids and Sedatives The induction dose requirements of propofol may be reduced in patients with intramuscular or intravenous premedication, particularly with opioids (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of propofol and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output. In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia. Analgesic Agents During maintenance of anesthesia or sedation, the rate of propofol administration should be adjusted according to the desir', 'DailyMed'),
(25023, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Opioids and Sedatives The induction dose requirements of propofol may be reduced in patients with intramuscular or intravenous premedication, particularly with opioids (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of propofol and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output. In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia. Analgesic Agents During maintenance of anesthesia or sedation, the rate of propofol administration should be adjusted according to the desir', 'DailyMed'),
(25366, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Opioids and Sedatives The induction dose requirements of propofol may be reduced in patients with intramuscular or intravenous premedication, particularly with opioids (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of propofol and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output. In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia. Analgesic Agents During maintenance of anesthesia or sedation, the rate of propofol administration should be adjusted according to the desir', 'DailyMed'),
(25767, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Opioids and Sedatives The induction dose requirements of propofol may be reduced in patients with intramuscular or intravenous premedication, particularly with opioids (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of propofol and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output. In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia. Analgesic Agents During maintenance of anesthesia or sedation, the rate of propofol administration should be adjusted according to the desir', 'DailyMed'),
(2828, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(2828, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(21703, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(21703, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(29811, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(29811, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(26611, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(26611, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(2822, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(2822, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(2825, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(2825, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(2823, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(2823, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(2826, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(2826, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(25683, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(25683, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(7201, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(7201, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(26612, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(26612, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(2824, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(2824, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(22439, 'caffeine', 'N/A', 'moderate', '[see Dosage and Administration (2.6), Clinical Pharmacology (12.3)] Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.', 'DailyMed'),
(22439, 'drug_class', 'N/A', 'moderate', '7.2 Potential for CLOZARIL to Affect Other Drugs Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).', 'DailyMed'),
(4605, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(4593, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(25195, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(8030, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(11301, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(25196, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(16799, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(25872, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(25190, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(35, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(4592, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(4588, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(18295, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(36, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(4170, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(4167, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(28118, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(28119, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(2945, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(25189, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(25871, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(4591, 'iron', 'N/A', 'major', 'Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.', 'DailyMed'),
(22256, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22262, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22257, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22270, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22264, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22259, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22252, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22251, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22266, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(17894, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22261, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(21652, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22268, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(22269, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(31759, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22253, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(2709, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22265, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22250, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22254, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(11156, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(14740, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(17812, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22263, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22260, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22267, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22249, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22258, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(22255, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(15508, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS Nephrotoxic Drugs and Diuretics: May increase the risk of renal failure; avoid concomitant use. (7.1, 7.2) Neurotoxic Drugs: May potentiate CNS toxicity of mannitol; avoid concomitant use. (7.3) Drugs Affected by Electrolyte Imbalances: May result in cardiac adverse reactions; monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens. (7.4) Renally Eliminated Agents: Concomitant use may decrease the effectiveness of agents that undergo significant renal elimination. However, concomitant use of mannitol and lithium may increase risk of lithium toxicity. If concomitant use is necessary, frequently monitor lithium concentrations and for signs of toxicity. (7.5) 7.1 Nephrotoxic Drugs Concomitant administration of nephrotoxic drugs (e.g., aminog', 'DailyMed'),
(14460, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Antihypertensive Drugs: Asenapine may cause hypotension. (5.7, 7.1, 12.3)  Paroxetine (CYP2D6 substrate and inhibitor): Reduce paroxetine by half when used in combination with asenapine. (7.1, 12.3) 7.1 Drugs Having Clinically Important Drug Interactions with Asenapine Table 12: Clinically Important Drug Interactions with Asenapine Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Antihypertensive Drugs Because of its 1-adrenergic antagonism with potential for inducing hypotension, asenapine may enhance the effects of certain antihypertensive agents [see Warnings and Precautions (5.7)]. Monitor blood pressure and adjust dosage of antihypertensive drug accordingly. Strong CYP1A2 Inhibitors (e.g., Fluvoxamine) Asenapine is metabolized by C', 'DailyMed'),
(14459, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Antihypertensive Drugs: Asenapine may cause hypotension. (5.7, 7.1, 12.3)  Paroxetine (CYP2D6 substrate and inhibitor): Reduce paroxetine by half when used in combination with asenapine. (7.1, 12.3) 7.1 Drugs Having Clinically Important Drug Interactions with Asenapine Table 12: Clinically Important Drug Interactions with Asenapine Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Antihypertensive Drugs Because of its 1-adrenergic antagonism with potential for inducing hypotension, asenapine may enhance the effects of certain antihypertensive agents [see Warnings and Precautions (5.7)]. Monitor blood pressure and adjust dosage of antihypertensive drug accordingly. Strong CYP1A2 Inhibitors (e.g., Fluvoxamine) Asenapine is metabolized by C', 'DailyMed'),
(10102, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Antihypertensive Drugs: Asenapine may cause hypotension. (5.7, 7.1, 12.3)  Paroxetine (CYP2D6 substrate and inhibitor): Reduce paroxetine by half when used in combination with asenapine. (7.1, 12.3) 7.1 Drugs Having Clinically Important Drug Interactions with Asenapine Table 12: Clinically Important Drug Interactions with Asenapine Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Antihypertensive Drugs Because of its 1-adrenergic antagonism with potential for inducing hypotension, asenapine may enhance the effects of certain antihypertensive agents [see Warnings and Precautions (5.7)]. Monitor blood pressure and adjust dosage of antihypertensive drug accordingly. Strong CYP1A2 Inhibitors (e.g., Fluvoxamine) Asenapine is metabolized by C', 'DailyMed'),
(14462, 'drug_class', 'N/A', 'major', '7 DRUG INTERACTIONS  Antihypertensive Drugs: Asenapine may cause hypotension. (5.7, 7.1, 12.3)  Paroxetine (CYP2D6 substrate and inhibitor): Reduce paroxetine by half when used in combination with asenapine. (7.1, 12.3) 7.1 Drugs Having Clinically Important Drug Interactions with Asenapine Table 12: Clinically Important Drug Interactions with Asenapine Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Antihypertensive Drugs Because of its 1-adrenergic antagonism with potential for inducing hypotension, asenapine may enhance the effects of certain antihypertensive agents [see Warnings and Precautions (5.7)]. Monitor blood pressure and adjust dosage of antihypertensive drug accordingly. Strong CYP1A2 Inhibitors (e.g., Fluvoxamine) Asenapine is metabolized by C', 'DailyMed'),
(28182, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(20056, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(27315, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(27218, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(14126, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(27219, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(20434, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(27220, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(27221, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(27222, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(20435, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(23168, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(20055, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(27223, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(23044, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(23831, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(20260, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(20538, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(27217, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(19669, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(26834, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(18462, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(23832, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(21673, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(23043, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(29600, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(14620, 'drug_class', 'N/A', 'severe', '7 DRUG INTERACTIONS Coadministration of amiodarone with a sofosbuvir-containing regimen may result in serious symptomatic bradycardia. ( 5.2, 6.2, 7.1) Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John''s wort) may alter the concentrations of sofosbuvir. ( 5.3, 7, 12.3) Consult the full prescribing information prior to use for potential drug-drug interactions. ( 5.2, 5.3, 7, 12.3) Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. ( 7.1) 7.1 Potentially Significant Drug Interactions Sofosbuvir is a substrate of dr', 'DailyMed'),
(6993, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Patients taking naltrexone may not benefit from opioid-containing medicines (see PRECAUTIONS, Pain Management). Because naltrexone is not a substrate for CYP drug metabolizing enzymes, inducers or inhibitors of these enzymes are unlikely to change the clearance of naltrexone. No clinical drug interaction studies have been performed with naltrexone to evaluate drug interactions, therefore prescribers should weigh the risks and benefits of concomitant drug use.', 'DailyMed'),
(721, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Patients taking naltrexone may not benefit from opioid-containing medicines (see PRECAUTIONS, Pain Management). Because naltrexone is not a substrate for CYP drug metabolizing enzymes, inducers or inhibitors of these enzymes are unlikely to change the clearance of naltrexone. No clinical drug interaction studies have been performed with naltrexone to evaluate drug interactions, therefore prescribers should weigh the risks and benefits of concomitant drug use.', 'DailyMed'),
(17233, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Patients taking naltrexone may not benefit from opioid-containing medicines (see PRECAUTIONS, Pain Management). Because naltrexone is not a substrate for CYP drug metabolizing enzymes, inducers or inhibitors of these enzymes are unlikely to change the clearance of naltrexone. No clinical drug interaction studies have been performed with naltrexone to evaluate drug interactions, therefore prescribers should weigh the risks and benefits of concomitant drug use.', 'DailyMed'),
(25953, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Patients taking naltrexone may not benefit from opioid-containing medicines (see PRECAUTIONS, Pain Management). Because naltrexone is not a substrate for CYP drug metabolizing enzymes, inducers or inhibitors of these enzymes are unlikely to change the clearance of naltrexone. No clinical drug interaction studies have been performed with naltrexone to evaluate drug interactions, therefore prescribers should weigh the risks and benefits of concomitant drug use.', 'DailyMed'),
(6738, 'drug_class', 'N/A', 'moderate', 'Drug Interactions Patients taking naltrexone may not benefit from opioid-containing medicines (see PRECAUTIONS, Pain Management). Because naltrexone is not a substrate for CYP drug metabolizing enzymes, inducers or inhibitors of these enzymes are unlikely to change the clearance of naltrexone. No clinical drug interaction studies have been performed with naltrexone to evaluate drug interactions, therefore prescribers should weigh the risks and benefits of concomitant drug use.', 'DailyMed'),
(15087, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(15087, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(15087, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(15087, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(15087, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(12970, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(12970, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(12970, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(12970, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(12970, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(32205, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(32205, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(32205, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(32205, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(32205, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(25608, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(25608, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(25608, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(25608, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(25608, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(20713, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(20713, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(20713, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(20713, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(20713, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(24576, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(24576, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(24576, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(24576, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(24576, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(1411, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(1411, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(1411, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(1411, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(1411, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(24449, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(24449, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(24449, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(24449, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(24449, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(13027, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(13027, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(13027, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(13027, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(13027, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(20623, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(20623, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(20623, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(20623, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(20623, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(28647, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(28647, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(28647, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(28647, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(28647, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(13025, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(13025, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(13025, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(13025, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(13025, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(25607, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(25607, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(25607, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(25607, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(25607, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(13021, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(13021, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(13021, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(13021, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(13021, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(24577, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(24577, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(24577, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(24577, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(24577, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(12963, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(12963, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(12963, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(12963, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(12963, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(12969, 'rabeprazole sodium', 'N/A', 'minor', 'Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.', 'DailyMed'),
(12969, 'iron', 'N/A', 'major', 'Patients need to be monitored ( 7.2 ) Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro ( 7.3 ) ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) ( 7.4 ) ACIPHEX may reduce the plasma levels of atazanavir ( 7.4 ) 7.1 Drugs metabolized by CYP450 Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system.', 'DailyMed'),
(12969, 'drug_class', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of', 'DailyMed'),
(12969, 'rabeprazole', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(12969, 'raberprazole sodium d/r', 'N/A', 'contraindicated', 'Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with rabeprazole sodium delayed-release tablets and instructions for preventing or managing them. Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. Intervention: Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets is contraindicated [see Contraindications (4)].', 'DailyMed'),
(23031, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(23031, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23031, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23029, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(23029, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23029, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13541, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(13541, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13541, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13411, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(13411, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13411, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(30957, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(30957, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(30957, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23026, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(23026, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23026, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23037, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(23037, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23037, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(30958, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(30958, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(30958, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(19161, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(19161, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(19161, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(5346, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(5346, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(5346, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23032, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(23032, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23032, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(26905, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(26905, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(26905, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(19359, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(19359, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(28226, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(28226, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(28226, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(25733, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(25733, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(25733, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(26091, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(26091, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(26091, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(20701, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(20701, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(20701, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(22895, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(22895, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(22895, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(2350, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(2350, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(2350, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(22894, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(22894, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(22894, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(5033, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(5033, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(5033, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23023, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(23023, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23023, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(6377, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(6377, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(6377, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(25554, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(25554, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(25554, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13141, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(13141, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13141, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(22990, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(22990, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(22990, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23030, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(23030, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23030, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23022, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(23022, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23022, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(19239, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(19239, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(19239, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(25255, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(25255, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(25255, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(4277, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(4277, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(4277, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(18179, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(18179, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(18179, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(8274, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(8274, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(8274, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(24171, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(24171, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(24171, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(3384, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(3384, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(3384, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(180, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(180, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(180, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(26354, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(26354, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(26354, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23041, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23041, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23028, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(23028, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23028, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(8371, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(8371, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(8371, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23040, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(23040, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(23040, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(1143, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(1143, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(1143, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(29299, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(29299, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(29299, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(22892, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(22892, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(22892, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(21423, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(21423, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(21423, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13363, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(13363, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(13363, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(22983, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(22983, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(22983, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(30761, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(30761, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(30761, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(31810, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(31810, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(31810, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(8375, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(8375, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(8375, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(25556, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(25556, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(25556, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(17759, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(17759, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(17759, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(11276, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(11276, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(11276, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(5115, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(5115, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(5115, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(7249, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.', 'DailyMed'),
(7249, 'zinc', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(7249, 'iron', 'N/A', 'minor', 'Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired.', 'DailyMed'),
(29615, 'caffeine', 'N/A', 'minor', 'Chronic administration of NUVIGIL at 250 mg did not affect the pharmacokinetics of caffeine (200 mg), a probe substrate for CYP1A2 activity.', 'DailyMed'),
(29615, 'drug_class', 'N/A', 'moderate', 'Effects of armodafinil on CYP3A4/5 Substrates The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by armodafinil via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with armodafinil [see CLINICAL PHARMACOLOGY (12.3)]. The effectiveness of steroidal contraceptives may be reduced when used with armodafinil and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with armodafinil and for one month after discontinuation of ar', 'DailyMed'),
(14413, 'caffeine', 'N/A', 'minor', 'Chronic administration of NUVIGIL at 250 mg did not affect the pharmacokinetics of caffeine (200 mg), a probe substrate for CYP1A2 activity.', 'DailyMed'),
(14413, 'drug_class', 'N/A', 'moderate', 'Effects of armodafinil on CYP3A4/5 Substrates The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by armodafinil via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with armodafinil [see CLINICAL PHARMACOLOGY (12.3)]. The effectiveness of steroidal contraceptives may be reduced when used with armodafinil and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with armodafinil and for one month after discontinuation of ar', 'DailyMed'),
(14415, 'caffeine', 'N/A', 'minor', 'Chronic administration of NUVIGIL at 250 mg did not affect the pharmacokinetics of caffeine (200 mg), a probe substrate for CYP1A2 activity.', 'DailyMed'),
(14415, 'drug_class', 'N/A', 'moderate', 'Effects of armodafinil on CYP3A4/5 Substrates The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by armodafinil via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with armodafinil [see CLINICAL PHARMACOLOGY (12.3)]. The effectiveness of steroidal contraceptives may be reduced when used with armodafinil and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with armodafinil and for one month after discontinuation of ar', 'DailyMed'),
(14414, 'caffeine', 'N/A', 'minor', 'Chronic administration of NUVIGIL at 250 mg did not affect the pharmacokinetics of caffeine (200 mg), a probe substrate for CYP1A2 activity.', 'DailyMed'),
(14414, 'drug_class', 'N/A', 'moderate', 'Effects of armodafinil on CYP3A4/5 Substrates The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by armodafinil via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with armodafinil [see CLINICAL PHARMACOLOGY (12.3)]. The effectiveness of steroidal contraceptives may be reduced when used with armodafinil and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with armodafinil and for one month after discontinuation of ar', 'DailyMed'),
(14412, 'caffeine', 'N/A', 'minor', 'Chronic administration of NUVIGIL at 250 mg did not affect the pharmacokinetics of caffeine (200 mg), a probe substrate for CYP1A2 activity.', 'DailyMed'),
(14412, 'drug_class', 'N/A', 'moderate', 'Effects of armodafinil on CYP3A4/5 Substrates The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by armodafinil via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with armodafinil [see CLINICAL PHARMACOLOGY (12.3)]. The effectiveness of steroidal contraceptives may be reduced when used with armodafinil and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with armodafinil and for one month after discontinuation of ar', 'DailyMed'),
(29614, 'caffeine', 'N/A', 'minor', 'Chronic administration of NUVIGIL at 250 mg did not affect the pharmacokinetics of caffeine (200 mg), a probe substrate for CYP1A2 activity.', 'DailyMed'),
(29614, 'drug_class', 'N/A', 'moderate', 'Effects of armodafinil on CYP3A4/5 Substrates The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by armodafinil via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with armodafinil [see CLINICAL PHARMACOLOGY (12.3)]. The effectiveness of steroidal contraceptives may be reduced when used with armodafinil and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with armodafinil and for one month after discontinuation of ar', 'DailyMed'),
(14416, 'caffeine', 'N/A', 'minor', 'Chronic administration of NUVIGIL at 250 mg did not affect the pharmacokinetics of caffeine (200 mg), a probe substrate for CYP1A2 activity.', 'DailyMed'),
(14416, 'drug_class', 'N/A', 'moderate', 'Effects of armodafinil on CYP3A4/5 Substrates The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by armodafinil via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with armodafinil [see CLINICAL PHARMACOLOGY (12.3)]. The effectiveness of steroidal contraceptives may be reduced when used with armodafinil and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with armodafinil and for one month after discontinuation of ar', 'DailyMed'),
(14411, 'caffeine', 'N/A', 'minor', 'Chronic administration of NUVIGIL at 250 mg did not affect the pharmacokinetics of caffeine (200 mg), a probe substrate for CYP1A2 activity.', 'DailyMed'),
(14411, 'drug_class', 'N/A', 'moderate', 'Effects of armodafinil on CYP3A4/5 Substrates The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by armodafinil via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with armodafinil [see CLINICAL PHARMACOLOGY (12.3)]. The effectiveness of steroidal contraceptives may be reduced when used with armodafinil and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with armodafinil and for one month after discontinuation of ar', 'DailyMed'),
(22842, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(15972, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(16003, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(2181, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(2180, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(2195, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(2799, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(22844, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(2798, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(2193, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(14875, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(1262, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(14873, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(2192, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(33080, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(1264, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(16004, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(22843, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(16555, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(1263, 'drug_class', 'N/A', 'minor', 'Drug Interactions Antacids The extent of absorption of cefaclor extended-release tablets is diminished if magnesium or aluminum hydroxide-containing antacids are taken within 1 hour of administration; H2 blockers do not alter either the rate or the extent of absorption of cefaclor extended-release tablets. Probenecid The renal excretion of cefaclor is inhibited by probenecid. Warfarin There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and warfarin concomitantly. No specific studies have been performed to rule in or rule out this potential drug/drug interaction.', 'DailyMed'),
(23672, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(23341, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(26214, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(8782, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(23332, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(23342, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(8781, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(22888, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(23337, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(23340, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(22370, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(23510, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(27798, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(8625, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(23411, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(32219, 'drug_class', 'N/A', 'contraindicated', '7. Drug Interactions CYP2D6 enzyme inhibitors may increase nebivolol levels (7.1) Reserpine or clonidine may produce excessive reduction of sympathetic activity. (7.2) Both digitalis glycosides and -blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. (7.3) Verapamil- or diltiazem-type calcium channel blockers may cause excessive reductions in heart rate, blood pressure, and cardiac contractility. (7.4) 7.1 CYP2D6 Inhibitors Use caution when BYSTOLIC is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.) [see Clinical Pharmacology (12.5)]. 7.2 Hypotensive Agents Do not use BYSTOLIC with other -blockers. Closely monitor patients receiving catecholamine-depleting drugs, such as res', 'DailyMed'),
(5848, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS CYP3A4 Inhibitors: May increase dasatinib drug levels and should be avoided. If coadministration cannot be avoided, monitor closely and consider reducing SPRYCEL dose. (2.1, 7.1) CYP3A4 Inducers: May decrease dasatinib drug levels. If coadministration cannot be avoided, consider increasing SPRYCEL dose. (2.1, 7.2) Antacids: May decrease dasatinib drug levels. Avoid simultaneous administration. If needed, administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. (7.2) H2 Antagonists/Proton Pump Inhibitors: May decrease dasatinib drug levels. Consider antacids in place of H2 antagonists or proton pump inhibitors. (7.2) 7.1 Drugs That May Increase Dasatinib Plasma Concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate. In a study of ', 'DailyMed'),
(19609, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS CYP3A4 Inhibitors: May increase dasatinib drug levels and should be avoided. If coadministration cannot be avoided, monitor closely and consider reducing SPRYCEL dose. (2.1, 7.1) CYP3A4 Inducers: May decrease dasatinib drug levels. If coadministration cannot be avoided, consider increasing SPRYCEL dose. (2.1, 7.2) Antacids: May decrease dasatinib drug levels. Avoid simultaneous administration. If needed, administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. (7.2) H2 Antagonists/Proton Pump Inhibitors: May decrease dasatinib drug levels. Consider antacids in place of H2 antagonists or proton pump inhibitors. (7.2) 7.1 Drugs That May Increase Dasatinib Plasma Concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate. In a study of ', 'DailyMed'),
(10837, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS CYP3A4 Inhibitors: May increase dasatinib drug levels and should be avoided. If coadministration cannot be avoided, monitor closely and consider reducing SPRYCEL dose. (2.1, 7.1) CYP3A4 Inducers: May decrease dasatinib drug levels. If coadministration cannot be avoided, consider increasing SPRYCEL dose. (2.1, 7.2) Antacids: May decrease dasatinib drug levels. Avoid simultaneous administration. If needed, administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. (7.2) H2 Antagonists/Proton Pump Inhibitors: May decrease dasatinib drug levels. Consider antacids in place of H2 antagonists or proton pump inhibitors. (7.2) 7.1 Drugs That May Increase Dasatinib Plasma Concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate. In a study of ', 'DailyMed'),
(5850, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS CYP3A4 Inhibitors: May increase dasatinib drug levels and should be avoided. If coadministration cannot be avoided, monitor closely and consider reducing SPRYCEL dose. (2.1, 7.1) CYP3A4 Inducers: May decrease dasatinib drug levels. If coadministration cannot be avoided, consider increasing SPRYCEL dose. (2.1, 7.2) Antacids: May decrease dasatinib drug levels. Avoid simultaneous administration. If needed, administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. (7.2) H2 Antagonists/Proton Pump Inhibitors: May decrease dasatinib drug levels. Consider antacids in place of H2 antagonists or proton pump inhibitors. (7.2) 7.1 Drugs That May Increase Dasatinib Plasma Concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate. In a study of ', 'DailyMed'),
(27431, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS CYP3A4 Inhibitors: May increase dasatinib drug levels and should be avoided. If coadministration cannot be avoided, monitor closely and consider reducing SPRYCEL dose. (2.1, 7.1) CYP3A4 Inducers: May decrease dasatinib drug levels. If coadministration cannot be avoided, consider increasing SPRYCEL dose. (2.1, 7.2) Antacids: May decrease dasatinib drug levels. Avoid simultaneous administration. If needed, administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. (7.2) H2 Antagonists/Proton Pump Inhibitors: May decrease dasatinib drug levels. Consider antacids in place of H2 antagonists or proton pump inhibitors. (7.2) 7.1 Drugs That May Increase Dasatinib Plasma Concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate. In a study of ', 'DailyMed'),
(5852, 'drug_class', 'N/A', 'moderate', '7 DRUG INTERACTIONS CYP3A4 Inhibitors: May increase dasatinib drug levels and should be avoided. If coadministration cannot be avoided, monitor closely and consider reducing SPRYCEL dose. (2.1, 7.1) CYP3A4 Inducers: May decrease dasatinib drug levels. If coadministration cannot be avoided, consider increasing SPRYCEL dose. (2.1, 7.2) Antacids: May decrease dasatinib drug levels. Avoid simultaneous administration. If needed, administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. (7.2) H2 Antagonists/Proton Pump Inhibitors: May decrease dasatinib drug levels. Consider antacids in place of H2 antagonists or proton pump inhibitors. (7.2) 7.1 Drugs That May Increase Dasatinib Plasma Concentrations CYP3A4 Inhibitors: Dasatinib is a CYP3A4 substrate. In a study of ', 'DailyMed'),
(14067, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(14067, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(14067, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(14067, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(5203, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(5203, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(5203, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(5203, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(4360, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(4360, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(4360, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(4360, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(12546, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(12546, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(12546, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(12546, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17257, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(17257, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(17257, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(17257, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(23323, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(23323, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(23323, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(23323, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(4994, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(4994, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(4994, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(4994, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(14152, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(14152, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(14152, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(14152, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(31820, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(31820, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(31820, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(31820, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(19201, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(19201, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(19201, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(19201, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(14151, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(14151, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(14151, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(14151, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(11598, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(11598, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(11598, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(11598, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(21162, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(21162, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(21162, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(21162, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(4993, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(4993, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(4993, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(4993, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(4960, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(4960, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(4960, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(4960, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(347, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(347, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(347, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(347, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(19208, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(19208, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(19208, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(19208, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(27679, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(27679, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(27679, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(27679, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(19147, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(19147, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(19147, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(19147, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(682, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(682, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(682, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(682, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(13446, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(13446, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(13446, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(13446, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(3666, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(3666, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(3666, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(3666, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(23324, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(23324, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(23324, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(23324, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(32275, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(32275, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(32275, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(32275, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(3664, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(3664, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(3664, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(3664, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(785, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(785, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(785, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(785, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(23322, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(23322, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(23322, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(23322, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(33255, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(33255, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(33255, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(33255, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(3665, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(3665, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(3665, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(3665, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(8612, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(8612, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(8612, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(8612, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(28496, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(28496, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(28496, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(28496, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(19202, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(19202, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(19202, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(19202, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(14150, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(14150, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(14150, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(14150, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(23321, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(23321, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(23321, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(23321, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(15757, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(15757, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(15757, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(15757, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(1992, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(1992, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(1992, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(1992, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(3663, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(3663, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(3663, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(3663, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(3542, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(3542, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(3542, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(3542, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(28730, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(28730, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(28730, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(28730, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(28497, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(28497, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(28497, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(28497, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(13070, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(13070, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(13070, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(13070, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(13531, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(13531, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(13531, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(13531, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(17642, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(17642, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(17642, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(17642, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(3667, 'drug_class', 'N/A', 'contraindicated', 'Drug interactions (See CLINICAL PHARMACOLOGY: Drug Interaction Studies and CONTRAINDICATIONS.) Clinically or potentially significant drug interactions between fluconazole and the following agents/classes have been observed. These are described in greater detail below: Oral hypoglycemicsCoumarin-type anticoagulantsPhenytoinCyclosporineRifampinTheophyllineTerfenadineCisaprideAstemizoleRifabutinTacrolimusShort-term benzodiazepines Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. Fluconazole reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these ag', 'DailyMed'),
(3667, 'hydrochlorothiazide', 'N/A', 'contraindicated', 'These are described in greater detail below: Oral hypoglycemics Coumarin-type anticoagulants Phenytoin Cyclosporine Rifampin Theophylline Terfenadine Cisapride Astemizole Rifabutin Voriconazole Tacrolimus Short-acting benzodiazepines Triazolam Oral Contraceptives Pimozide Hydrochlorothiazide Alfentanil Amitriptyline, nortriptyline Amphotericin B Azithromycin Carbamazepine Calcium Channel Blockers Celecoxib Cyclophosphamide Fentanyl Halofantrine HMG-CoA reductase inhibitors Losartan Methadone Non-steroidal anti-inflammatory drugs Prednisone Saquinavir Sirolimus Vinca Alkaloids Vitamin A Zidovudine Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association', 'DailyMed'),
(3667, 'amlodipine', 'N/A', 'minor', 'Calcium Channel Blockers: Certain dihydropyridine calcium channel antagonists (nifedipine, isradipine, amlodipine, and felodipine) are metabolized by CYP3A4.', 'DailyMed'),
(3667, 'sodium chloride', 'N/A', 'moderate', 'Patients treated with Fluconazole in Sodium Chloride Injection, who are also concomitantly treated with drugs with a narrow therapeutic window metabolized through CYP2C9 and CYP3A4, should be monitored for adverse reactions associated with the concomitantly administered drugs.', 'DailyMed'),
(30604, 'drug_class', 'N/A', 'severe', 'Drug Interactions Aminoglutethimide Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. Amphotericin B injection and potassium-depleting agents When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions, Hepatic Enzyme Inhibitors ). Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness', 'DailyMed'),
(10673, 'drug_class', 'N/A', 'severe', 'Drug Interactions Aminoglutethimide Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. Amphotericin B injection and potassium-depleting agents When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions, Hepatic Enzyme Inhibitors ). Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness', 'DailyMed'),
(30605, 'drug_class', 'N/A', 'severe', 'Drug Interactions Aminoglutethimide Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. Amphotericin B injection and potassium-depleting agents When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions, Hepatic Enzyme Inhibitors ). Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness', 'DailyMed'),
(27261, 'drug_class', 'N/A', 'severe', 'Drug Interactions Aminoglutethimide Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. Amphotericin B injection and potassium-depleting agents When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure. Antibiotics Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions, Hepatic Enzyme Inhibitors ). Anticholinesterases Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness', 'DailyMed'),
(13441, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (e.g. Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of ACTONEL (7.1). 7.1 Calcium Supplements/Antacids Co-administration of ACTONEL and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of ACTONEL. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with ACTONEL 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months ', 'DailyMed'),
(13441, 'iron', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(26173, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (e.g. Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of ACTONEL (7.1). 7.1 Calcium Supplements/Antacids Co-administration of ACTONEL and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of ACTONEL. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with ACTONEL 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months ', 'DailyMed'),
(26173, 'iron', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(13437, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (e.g. Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of ACTONEL (7.1). 7.1 Calcium Supplements/Antacids Co-administration of ACTONEL and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of ACTONEL. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with ACTONEL 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months ', 'DailyMed'),
(13437, 'iron', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(26158, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (e.g. Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of ACTONEL (7.1). 7.1 Calcium Supplements/Antacids Co-administration of ACTONEL and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of ACTONEL. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with ACTONEL 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months ', 'DailyMed'),
(26158, 'iron', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(119, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (e.g. Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of ACTONEL (7.1). 7.1 Calcium Supplements/Antacids Co-administration of ACTONEL and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of ACTONEL. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with ACTONEL 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months ', 'DailyMed'),
(119, 'iron', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(13432, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (e.g. Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of ACTONEL (7.1). 7.1 Calcium Supplements/Antacids Co-administration of ACTONEL and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of ACTONEL. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with ACTONEL 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months ', 'DailyMed'),
(13432, 'iron', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(13440, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (e.g. Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of ACTONEL (7.1). 7.1 Calcium Supplements/Antacids Co-administration of ACTONEL and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of ACTONEL. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with ACTONEL 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months ', 'DailyMed'),
(13440, 'iron', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(26165, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (e.g. Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of ACTONEL (7.1). 7.1 Calcium Supplements/Antacids Co-administration of ACTONEL and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of ACTONEL. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with ACTONEL 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months ', 'DailyMed'),
(26165, 'iron', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(9874, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS No specific drug-drug interaction studies were performed. Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (e.g. Cytochrome P450). Calcium, antacids, or oral medications containing divalent cations interfere with the absorption of ACTONEL (7.1). 7.1 Calcium Supplements/Antacids Co-administration of ACTONEL and calcium, antacids, or oral medications containing divalent cations will interfere with the absorption of ACTONEL. 7.2 Hormone Replacement Therapy One study of about 500 early postmenopausal women has been conducted to date in which treatment with ACTONEL 5 mg daily plus estrogen replacement therapy was compared to estrogen replacement therapy alone. Exposure to study drugs was approximately 12 to 18 months ', 'DailyMed'),
(9874, 'iron', 'N/A', 'minor', 'Calcium supplements, antacids, proton pump inhibitors (PPIs), H2 blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium (7.1, 7.2) 7.1 Calcium Supplements/Antacids When risedronate sodium was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [see Clinical Pharmacology (12.3)]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of risedronate sodium and should not be taken together.', 'DailyMed'),
(18468, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(12031, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(12039, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(12033, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(18469, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(8739, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(12038, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(8740, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(8738, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(28925, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(28924, 'drug_class', 'N/A', 'major', 'Drug Interactions Centrally Acting AgentsIf diazepam is to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. AlcoholConcomitant use with alcohol is not recommended due to enhancement of the sedative effect. AntacidsDiazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slowe', 'DailyMed'),
(22907, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(398, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(27117, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(1679, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(13793, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(27854, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(15441, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(22631, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(4090, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(29642, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(4088, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(18196, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(8587, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(18202, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(399, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(20072, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(1680, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(18199, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(22630, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(18198, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(15440, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(22775, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(22628, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(20073, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(23715, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(22629, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(1681, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS In clinical studies, the concurrent administration of ASMANEX TWISTHALER and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse reactions. 7.1 Inhibitors of Cytochrome P450 3A4 Ketoconazole, a strong inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing [see Clinical Pharmacology (12.3) ].', 'DailyMed'),
(27805, 'drug_class', 'N/A', 'minor', '7 DRUG INTERACTIONS No formal drug-drug interaction studies were conducted. In Trial 1, the proportions of children in the placebo and Synagis groups who received routine childhood vaccines, influenza vaccine, bronchodilators, or corticosteroids were similar and no incremental increase in adverse reactions was observed among children receiving these agents.', 'DailyMed'),
(23699, 'salicylic acid', 'N/A', 'major', 'Other Concomitant Therapy: Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, -blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.', 'DailyMed'),
(25403, 'salicylic acid', 'N/A', 'major', 'Other Concomitant Therapy: Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, -blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.', 'DailyMed'),
(19040, 'salicylic acid', 'N/A', 'major', 'Other Concomitant Therapy: Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, -blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.', 'DailyMed'),
(25330, 'salicylic acid', 'N/A', 'major', 'Other Concomitant Therapy: Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, -blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(25399, 'salicylic acid', 'N/A', 'major', 'Other Concomitant Therapy: Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, -blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.', 'DailyMed'),
(25372, 'salicylic acid', 'N/A', 'major', 'Other Concomitant Therapy: Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, -blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.', 'DailyMed'),
(4866, 'salicylic acid', 'N/A', 'major', 'Other Concomitant Therapy: Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, -blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.', 'DailyMed'),
(26382, 'salicylic acid', 'N/A', 'major', 'Other Concomitant Therapy: Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, -blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.', 'DailyMed'),
(22859, 'salicylic acid', 'N/A', 'major', 'Other Concomitant Therapy: Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, -blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.', 'DailyMed'),
(33561, 'salicylic acid', 'N/A', 'major', 'Other Concomitant Therapy: Although specific interaction studies were not performed, finasteride tablets USP was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, -blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.', 'DailyMed'),
(77, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(239, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(20359, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(13101, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(24463, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(13466, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(24470, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(13358, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(27226, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(13374, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(7748, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(13464, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(13458, 'salicylic acid', 'N/A', 'moderate', 'Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with adapalene gel.', 'DailyMed'),
(11862, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(11862, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(11862, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11862, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(11862, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(11862, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(11862, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(11862, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(11862, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(11862, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(11862, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(11862, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11862, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(11862, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11862, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11862, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11862, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(11862, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11862, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11862, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(11862, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11862, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(11862, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(11862, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(11862, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(11862, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(11862, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(11862, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11862, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11862, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(11862, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(11862, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(11862, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(11862, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11862, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(11862, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(11862, 'selegiline hydrochloride', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)].', 'DailyMed'),
(11862, 'ondansetron tablets', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(11862, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11862, 'methadone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11862, 'fentanyl citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'sufentanil citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'oxycodone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'sumatriptan succinate, ondansetron', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(11862, 'buprenorphine hydrochloride and naloxone hydrochloride dihydrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'ritonavir 100 mg', 'N/A', 'minor', 'Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(11862, 'nalbuphine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients ].', 'DailyMed'),
(11862, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(11862, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11862, 'darunavir', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11862, 'buprenorphine and naloxone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'tapentadol hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'codeine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'protriptyline hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking ULTRAM (tramadol hydrochloride).', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(11862, 'sufentanil', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (e.g., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'oxycodone hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'darunavir ethanolate and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11862, 'venlafaxine hydrochloride, extended release', 'N/A', 'minor', '(7.10) Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St.', 'DailyMed'),
(11862, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(11862, 'atropa belladonna and opium', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAOI) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'darunavir 600 mg', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11862, 'meperidine hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of DEMEROL Tablets or Oral Solution and/or precipitate withdrawal symptoms.', 'DailyMed'),
(11862, 'remifentanil hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'butalbital, acetaminophen, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'fentanyl transdermal', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'tramadol hcl', 'N/A', 'severe', 'Drug Interactions Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse e', 'DailyMed'),
(11862, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'hydrocodone bitartrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'levorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(11862, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11862, 'oxycodone hydrochloride oral solution', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone) monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'hydrocodone bitartrate and ibuprofen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine,metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome (see PRECAUTIONS: Information for Patients ).', 'DailyMed'),
(11862, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(11862, 'buprenorphine sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'buprenorphine sublingual c-iii', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'ondansetron hcl', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(11862, 'venlafaxine hcl', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'cyclobenzaprine hcl', 'N/A', 'severe', 'Drug Interactions Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(11862, 'oliceridine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs,) serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'tramadol hcl er', 'N/A', 'major', 'Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.', 'DailyMed'),
(11862, 'venlafaxine hcl er', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11862, 'cyclobenzaprine hcl er', 'N/A', 'severe', 'Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release capsules may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(11862, 'alprazolam c-iv', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(11862, 'butorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; INFORMATION FOR PATIENTS ].', 'DailyMed'),
(11862, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11862, 'oxycodone hydrochloride and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(11862, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11862, 'atazanavir and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.', 'DailyMed'),
(11862, 'cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11862, 'safinamide mesylate', 'N/A', 'contraindicated', '7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2)].', 'DailyMed'),
(11862, 'pentazocine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11862, 'methadone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11862, 'lenacapavir sodium', 'N/A', 'minor', 'Tramadol  tramadol A decrease in dose may be needed for tramadol with concomitant use.', 'DailyMed'),
(11862, 'tramadol hcl and acetaminophen', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 includes clinically significant interactions with tramadol hydrochloride and acetaminophen tablets. Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride and Acetaminophen Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride and acetaminophen tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride and acetaminophen tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had deve', 'DailyMed'),
(13885, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(13885, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(13885, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(13885, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(13885, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(13885, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(13885, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(13885, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(13885, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(13885, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(13885, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(13885, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(13885, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(13885, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(13885, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(13885, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(13885, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(13885, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13885, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13885, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(13885, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(13885, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(13885, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13885, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(13885, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(13885, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(13885, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13885, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13885, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13885, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(13885, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(13885, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(13885, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(13885, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(13885, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(13885, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(13885, 'selegiline hydrochloride', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)].', 'DailyMed'),
(13885, 'ondansetron tablets', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(13885, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13885, 'methadone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13885, 'fentanyl citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'sufentanil citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'oxycodone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'sumatriptan succinate, ondansetron', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(13885, 'buprenorphine hydrochloride and naloxone hydrochloride dihydrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'ritonavir 100 mg', 'N/A', 'minor', 'Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(13885, 'nalbuphine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients ].', 'DailyMed'),
(13885, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(13885, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13885, 'darunavir', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(13885, 'buprenorphine and naloxone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'tapentadol hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'codeine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'protriptyline hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking ULTRAM (tramadol hydrochloride).', 'DailyMed'),
(13885, 'sufentanil', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (e.g., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'oxycodone hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'darunavir ethanolate and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(13885, 'venlafaxine hydrochloride, extended release', 'N/A', 'minor', '(7.10) Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St.', 'DailyMed'),
(13885, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(13885, 'atropa belladonna and opium', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAOI) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'darunavir 600 mg', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(13885, 'meperidine hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of DEMEROL Tablets or Oral Solution and/or precipitate withdrawal symptoms.', 'DailyMed'),
(13885, 'remifentanil hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'butalbital, acetaminophen, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'fentanyl transdermal', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'tramadol hcl', 'N/A', 'severe', 'Drug Interactions Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse e', 'DailyMed'),
(13885, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'hydrocodone bitartrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'levorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(13885, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(13885, 'oxycodone hydrochloride oral solution', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone) monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'hydrocodone bitartrate and ibuprofen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine,metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome (see PRECAUTIONS: Information for Patients ).', 'DailyMed'),
(13885, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(13885, 'buprenorphine sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'buprenorphine sublingual c-iii', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'ondansetron hcl', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(13885, 'venlafaxine hcl', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'cyclobenzaprine hcl', 'N/A', 'severe', 'Drug Interactions Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(13885, 'oliceridine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs,) serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'tramadol hcl er', 'N/A', 'major', 'Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.', 'DailyMed'),
(13885, 'venlafaxine hcl er', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(13885, 'cyclobenzaprine hcl er', 'N/A', 'severe', 'Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release capsules may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(13885, 'alprazolam c-iv', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(13885, 'butorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; INFORMATION FOR PATIENTS ].', 'DailyMed'),
(13885, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(13885, 'oxycodone hydrochloride and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(13885, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(13885, 'atazanavir and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.', 'DailyMed'),
(13885, 'cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(13885, 'safinamide mesylate', 'N/A', 'contraindicated', '7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2)].', 'DailyMed'),
(13885, 'pentazocine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(13885, 'methadone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(13885, 'lenacapavir sodium', 'N/A', 'minor', 'Tramadol  tramadol A decrease in dose may be needed for tramadol with concomitant use.', 'DailyMed'),
(13885, 'tramadol hcl and acetaminophen', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 includes clinically significant interactions with tramadol hydrochloride and acetaminophen tablets. Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride and Acetaminophen Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride and acetaminophen tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride and acetaminophen tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had deve', 'DailyMed'),
(11150, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(11150, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(11150, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11150, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(11150, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(11150, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(11150, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(11150, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(11150, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(11150, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(11150, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(11150, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11150, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(11150, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11150, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11150, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11150, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(11150, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(11150, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11150, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(11150, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11150, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(11150, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(11150, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(11150, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(11150, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(11150, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(11150, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11150, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11150, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(11150, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(11150, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(11150, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(11150, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11150, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(11150, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(11150, 'selegiline hydrochloride', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)].', 'DailyMed'),
(11150, 'ondansetron tablets', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(11150, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11150, 'methadone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11150, 'fentanyl citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'sufentanil citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'oxycodone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'sumatriptan succinate, ondansetron', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(11150, 'buprenorphine hydrochloride and naloxone hydrochloride dihydrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'ritonavir 100 mg', 'N/A', 'minor', 'Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(11150, 'nalbuphine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients ].', 'DailyMed'),
(11150, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(11150, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11150, 'darunavir', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11150, 'buprenorphine and naloxone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'tapentadol hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'codeine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'protriptyline hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking ULTRAM (tramadol hydrochloride).', 'DailyMed'),
(11150, 'sufentanil', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (e.g., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'oxycodone hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'darunavir ethanolate and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11150, 'venlafaxine hydrochloride, extended release', 'N/A', 'minor', '(7.10) Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St.', 'DailyMed'),
(11150, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(11150, 'atropa belladonna and opium', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAOI) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'darunavir 600 mg', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11150, 'meperidine hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of DEMEROL Tablets or Oral Solution and/or precipitate withdrawal symptoms.', 'DailyMed'),
(11150, 'remifentanil hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'butalbital, acetaminophen, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'fentanyl transdermal', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'tramadol hcl', 'N/A', 'severe', 'Drug Interactions Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse e', 'DailyMed'),
(11150, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'hydrocodone bitartrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'levorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(11150, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11150, 'oxycodone hydrochloride oral solution', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone) monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'hydrocodone bitartrate and ibuprofen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine,metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome (see PRECAUTIONS: Information for Patients ).', 'DailyMed'),
(11150, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(11150, 'buprenorphine sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'buprenorphine sublingual c-iii', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'ondansetron hcl', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(11150, 'venlafaxine hcl', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'cyclobenzaprine hcl', 'N/A', 'severe', 'Drug Interactions Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(11150, 'oliceridine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs,) serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'tramadol hcl er', 'N/A', 'major', 'Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.', 'DailyMed'),
(11150, 'venlafaxine hcl er', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11150, 'cyclobenzaprine hcl er', 'N/A', 'severe', 'Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release capsules may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(11150, 'alprazolam c-iv', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(11150, 'butorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; INFORMATION FOR PATIENTS ].', 'DailyMed'),
(11150, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11150, 'oxycodone hydrochloride and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(11150, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11150, 'atazanavir and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.', 'DailyMed'),
(11150, 'cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11150, 'safinamide mesylate', 'N/A', 'contraindicated', '7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2)].', 'DailyMed'),
(11150, 'pentazocine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11150, 'methadone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11150, 'lenacapavir sodium', 'N/A', 'minor', 'Tramadol  tramadol A decrease in dose may be needed for tramadol with concomitant use.', 'DailyMed'),
(11150, 'tramadol hcl and acetaminophen', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 includes clinically significant interactions with tramadol hydrochloride and acetaminophen tablets. Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride and Acetaminophen Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride and acetaminophen tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride and acetaminophen tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had deve', 'DailyMed'),
(23943, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(23943, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(23943, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(23943, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(23943, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23943, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(23943, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(23943, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(23943, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(23943, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(23943, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(23943, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(23943, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(23943, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(23943, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(23943, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(23943, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(23943, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23943, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23943, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(23943, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(23943, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(23943, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23943, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(23943, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(23943, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(23943, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23943, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23943, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23943, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(23943, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(23943, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(23943, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(23943, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(23943, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(23943, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(23943, 'selegiline hydrochloride', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)].', 'DailyMed'),
(23943, 'ondansetron tablets', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(23943, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23943, 'methadone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23943, 'fentanyl citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'sufentanil citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'oxycodone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'sumatriptan succinate, ondansetron', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(23943, 'buprenorphine hydrochloride and naloxone hydrochloride dihydrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'ritonavir 100 mg', 'N/A', 'minor', 'Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(23943, 'nalbuphine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients ].', 'DailyMed'),
(23943, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(23943, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(23943, 'darunavir', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(23943, 'buprenorphine and naloxone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'tapentadol hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'codeine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'protriptyline hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking ULTRAM (tramadol hydrochloride).', 'DailyMed'),
(23943, 'sufentanil', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (e.g., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'oxycodone hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'darunavir ethanolate and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(23943, 'venlafaxine hydrochloride, extended release', 'N/A', 'minor', '(7.10) Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St.', 'DailyMed'),
(23943, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(23943, 'atropa belladonna and opium', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAOI) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'darunavir 600 mg', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(23943, 'meperidine hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of DEMEROL Tablets or Oral Solution and/or precipitate withdrawal symptoms.', 'DailyMed'),
(23943, 'remifentanil hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'butalbital, acetaminophen, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'fentanyl transdermal', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'tramadol hcl', 'N/A', 'severe', 'Drug Interactions Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse e', 'DailyMed'),
(23943, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'hydrocodone bitartrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'levorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(23943, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(23943, 'oxycodone hydrochloride oral solution', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone) monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'hydrocodone bitartrate and ibuprofen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine,metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome (see PRECAUTIONS: Information for Patients ).', 'DailyMed'),
(23943, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(23943, 'buprenorphine sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'buprenorphine sublingual c-iii', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'ondansetron hcl', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(23943, 'venlafaxine hcl', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'cyclobenzaprine hcl', 'N/A', 'severe', 'Drug Interactions Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(23943, 'oliceridine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs,) serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'tramadol hcl er', 'N/A', 'major', 'Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.', 'DailyMed'),
(23943, 'venlafaxine hcl er', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(23943, 'cyclobenzaprine hcl er', 'N/A', 'severe', 'Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release capsules may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(23943, 'alprazolam c-iv', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(23943, 'butorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; INFORMATION FOR PATIENTS ].', 'DailyMed'),
(23943, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(23943, 'oxycodone hydrochloride and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(23943, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(23943, 'atazanavir and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.', 'DailyMed'),
(23943, 'cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(23943, 'safinamide mesylate', 'N/A', 'contraindicated', '7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2)].', 'DailyMed'),
(23943, 'pentazocine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(23943, 'methadone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(23943, 'lenacapavir sodium', 'N/A', 'minor', 'Tramadol  tramadol A decrease in dose may be needed for tramadol with concomitant use.', 'DailyMed'),
(23943, 'tramadol hcl and acetaminophen', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 includes clinically significant interactions with tramadol hydrochloride and acetaminophen tablets. Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride and Acetaminophen Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride and acetaminophen tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride and acetaminophen tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had deve', 'DailyMed'),
(28388, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(28388, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(28388, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28388, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(28388, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(28388, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(28388, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(28388, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(28388, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(28388, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(28388, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(28388, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28388, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(28388, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28388, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28388, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28388, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(28388, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28388, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28388, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(28388, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28388, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(28388, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(28388, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(28388, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(28388, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(28388, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(28388, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28388, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28388, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(28388, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(28388, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(28388, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(28388, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28388, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(28388, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(28388, 'selegiline hydrochloride', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)].', 'DailyMed'),
(28388, 'ondansetron tablets', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(28388, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28388, 'methadone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28388, 'fentanyl citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'sufentanil citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'oxycodone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'sumatriptan succinate, ondansetron', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(28388, 'buprenorphine hydrochloride and naloxone hydrochloride dihydrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'ritonavir 100 mg', 'N/A', 'minor', 'Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(28388, 'nalbuphine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients ].', 'DailyMed'),
(28388, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(28388, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28388, 'darunavir', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28388, 'buprenorphine and naloxone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'tapentadol hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'codeine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'protriptyline hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking ULTRAM (tramadol hydrochloride).', 'DailyMed'),
(28388, 'sufentanil', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (e.g., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'oxycodone hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'darunavir ethanolate and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28388, 'venlafaxine hydrochloride, extended release', 'N/A', 'minor', '(7.10) Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St.', 'DailyMed'),
(28388, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(28388, 'atropa belladonna and opium', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAOI) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'darunavir 600 mg', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28388, 'meperidine hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of DEMEROL Tablets or Oral Solution and/or precipitate withdrawal symptoms.', 'DailyMed'),
(28388, 'remifentanil hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'butalbital, acetaminophen, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'fentanyl transdermal', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(28388, 'tramadol hcl', 'N/A', 'severe', 'Drug Interactions Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse e', 'DailyMed'),
(28388, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'hydrocodone bitartrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'levorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(28388, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28388, 'oxycodone hydrochloride oral solution', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone) monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'hydrocodone bitartrate and ibuprofen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine,metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome (see PRECAUTIONS: Information for Patients ).', 'DailyMed'),
(28388, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(28388, 'buprenorphine sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'buprenorphine sublingual c-iii', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'ondansetron hcl', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(28388, 'venlafaxine hcl', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'cyclobenzaprine hcl', 'N/A', 'severe', 'Drug Interactions Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(28388, 'oliceridine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs,) serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'tramadol hcl er', 'N/A', 'major', 'Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.', 'DailyMed'),
(28388, 'venlafaxine hcl er', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28388, 'cyclobenzaprine hcl er', 'N/A', 'severe', 'Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release capsules may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(28388, 'alprazolam c-iv', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(28388, 'butorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; INFORMATION FOR PATIENTS ].', 'DailyMed'),
(28388, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28388, 'oxycodone hydrochloride and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(28388, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28388, 'atazanavir and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.', 'DailyMed'),
(28388, 'cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28388, 'safinamide mesylate', 'N/A', 'contraindicated', '7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2)].', 'DailyMed'),
(28388, 'pentazocine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28388, 'methadone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28388, 'lenacapavir sodium', 'N/A', 'minor', 'Tramadol  tramadol A decrease in dose may be needed for tramadol with concomitant use.', 'DailyMed'),
(28388, 'tramadol hcl and acetaminophen', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 includes clinically significant interactions with tramadol hydrochloride and acetaminophen tablets. Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride and Acetaminophen Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride and acetaminophen tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride and acetaminophen tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had deve', 'DailyMed'),
(11579, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(11579, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(11579, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(11579, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(11579, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(11579, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(11579, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(11579, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(11579, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(11579, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(11579, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(11579, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11579, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(11579, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11579, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11579, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11579, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(11579, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11579, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11579, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(11579, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11579, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(11579, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(11579, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(11579, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(11579, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(11579, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(11579, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11579, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11579, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(11579, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(11579, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(11579, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(11579, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11579, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(11579, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(11579, 'selegiline hydrochloride', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)].', 'DailyMed'),
(11579, 'ondansetron tablets', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(11579, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11579, 'methadone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11579, 'fentanyl citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'sufentanil citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'oxycodone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'sumatriptan succinate, ondansetron', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(11579, 'buprenorphine hydrochloride and naloxone hydrochloride dihydrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'ritonavir 100 mg', 'N/A', 'minor', 'Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(11579, 'nalbuphine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients ].', 'DailyMed'),
(11579, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(11579, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11579, 'darunavir', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11579, 'buprenorphine and naloxone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'tapentadol hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'codeine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'protriptyline hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking ULTRAM (tramadol hydrochloride).', 'DailyMed'),
(11579, 'sufentanil', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (e.g., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'oxycodone hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'darunavir ethanolate and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11579, 'venlafaxine hydrochloride, extended release', 'N/A', 'minor', '(7.10) Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St.', 'DailyMed'),
(11579, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(11579, 'atropa belladonna and opium', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAOI) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'darunavir 600 mg', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11579, 'meperidine hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of DEMEROL Tablets or Oral Solution and/or precipitate withdrawal symptoms.', 'DailyMed'),
(11579, 'remifentanil hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'butalbital, acetaminophen, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'fentanyl transdermal', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'tramadol hcl', 'N/A', 'severe', 'Drug Interactions Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse e', 'DailyMed'),
(11579, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'hydrocodone bitartrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'levorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(11579, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11579, 'oxycodone hydrochloride oral solution', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone) monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'hydrocodone bitartrate and ibuprofen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine,metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome (see PRECAUTIONS: Information for Patients ).', 'DailyMed'),
(11579, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(11579, 'buprenorphine sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'buprenorphine sublingual c-iii', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'ondansetron hcl', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(11579, 'venlafaxine hcl', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'cyclobenzaprine hcl', 'N/A', 'severe', 'Drug Interactions Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(11579, 'oliceridine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs,) serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'tramadol hcl er', 'N/A', 'major', 'Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.', 'DailyMed'),
(11579, 'venlafaxine hcl er', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(11579, 'cyclobenzaprine hcl er', 'N/A', 'severe', 'Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release capsules may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(11579, 'alprazolam c-iv', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(11579, 'butorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; INFORMATION FOR PATIENTS ].', 'DailyMed'),
(11579, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11579, 'oxycodone hydrochloride and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(11579, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(11579, 'atazanavir and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.', 'DailyMed'),
(11579, 'cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(11579, 'safinamide mesylate', 'N/A', 'contraindicated', '7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2)].', 'DailyMed'),
(11579, 'pentazocine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(11579, 'methadone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(11579, 'lenacapavir sodium', 'N/A', 'minor', 'Tramadol  tramadol A decrease in dose may be needed for tramadol with concomitant use.', 'DailyMed'),
(11579, 'tramadol hcl and acetaminophen', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 includes clinically significant interactions with tramadol hydrochloride and acetaminophen tablets. Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride and Acetaminophen Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride and acetaminophen tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride and acetaminophen tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had deve', 'DailyMed'),
(28385, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(28385, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(28385, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28385, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(28385, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(28385, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(28385, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(28385, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(28385, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(28385, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(28385, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(28385, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28385, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(28385, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28385, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28385, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28385, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(28385, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28385, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28385, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(28385, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28385, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(28385, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(28385, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(28385, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(28385, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(28385, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(28385, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28385, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28385, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(28385, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(28385, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(28385, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(28385, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28385, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(28385, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(28385, 'selegiline hydrochloride', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)].', 'DailyMed'),
(28385, 'ondansetron tablets', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(28385, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28385, 'methadone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28385, 'fentanyl citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'sufentanil citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'oxycodone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'sumatriptan succinate, ondansetron', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(28385, 'buprenorphine hydrochloride and naloxone hydrochloride dihydrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'ritonavir 100 mg', 'N/A', 'minor', 'Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(28385, 'nalbuphine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients ].', 'DailyMed'),
(28385, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(28385, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28385, 'darunavir', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28385, 'buprenorphine and naloxone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'tapentadol hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'codeine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'protriptyline hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking ULTRAM (tramadol hydrochloride).', 'DailyMed'),
(28385, 'sufentanil', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (e.g., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'oxycodone hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'darunavir ethanolate and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28385, 'venlafaxine hydrochloride, extended release', 'N/A', 'minor', '(7.10) Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St.', 'DailyMed'),
(28385, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(28385, 'atropa belladonna and opium', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAOI) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'darunavir 600 mg', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28385, 'meperidine hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of DEMEROL Tablets or Oral Solution and/or precipitate withdrawal symptoms.', 'DailyMed'),
(28385, 'remifentanil hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'butalbital, acetaminophen, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'fentanyl transdermal', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'tramadol hcl', 'N/A', 'severe', 'Drug Interactions Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse e', 'DailyMed'),
(28385, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'hydrocodone bitartrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'levorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(28385, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28385, 'oxycodone hydrochloride oral solution', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone) monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'hydrocodone bitartrate and ibuprofen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine,metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome (see PRECAUTIONS: Information for Patients ).', 'DailyMed'),
(28385, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(28385, 'buprenorphine sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'buprenorphine sublingual c-iii', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'ondansetron hcl', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(28385, 'venlafaxine hcl', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'cyclobenzaprine hcl', 'N/A', 'severe', 'Drug Interactions Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(28385, 'oliceridine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs,) serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'tramadol hcl er', 'N/A', 'major', 'Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.', 'DailyMed'),
(28385, 'venlafaxine hcl er', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28385, 'cyclobenzaprine hcl er', 'N/A', 'severe', 'Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release capsules may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(28385, 'alprazolam c-iv', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(28385, 'butorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; INFORMATION FOR PATIENTS ].', 'DailyMed'),
(28385, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28385, 'oxycodone hydrochloride and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(28385, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28385, 'atazanavir and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.', 'DailyMed'),
(28385, 'cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28385, 'safinamide mesylate', 'N/A', 'contraindicated', '7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2)].', 'DailyMed'),
(28385, 'pentazocine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28385, 'methadone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28385, 'lenacapavir sodium', 'N/A', 'minor', 'Tramadol  tramadol A decrease in dose may be needed for tramadol with concomitant use.', 'DailyMed'),
(28385, 'tramadol hcl and acetaminophen', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 includes clinically significant interactions with tramadol hydrochloride and acetaminophen tablets. Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride and Acetaminophen Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride and acetaminophen tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride and acetaminophen tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had deve', 'DailyMed'),
(484, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(484, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(484, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(484, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(484, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(484, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(484, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(484, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(484, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(484, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(484, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(484, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(484, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(484, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(484, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(484, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(484, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(484, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(484, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(484, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(484, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(484, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(484, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(484, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(484, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(484, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(484, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(484, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(484, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(484, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(484, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(484, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(484, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(484, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(484, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(484, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(484, 'selegiline hydrochloride', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)].', 'DailyMed'),
(484, 'ondansetron tablets', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(484, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(484, 'methadone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(484, 'fentanyl citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'sufentanil citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'oxycodone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'sumatriptan succinate, ondansetron', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(484, 'buprenorphine hydrochloride and naloxone hydrochloride dihydrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'ritonavir 100 mg', 'N/A', 'minor', 'Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(484, 'nalbuphine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients ].', 'DailyMed'),
(484, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(484, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(484, 'darunavir', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(484, 'buprenorphine and naloxone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'tapentadol hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'codeine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'protriptyline hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking ULTRAM (tramadol hydrochloride).', 'DailyMed'),
(484, 'sufentanil', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (e.g., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'oxycodone hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'darunavir ethanolate and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(484, 'venlafaxine hydrochloride, extended release', 'N/A', 'minor', '(7.10) Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St.', 'DailyMed'),
(484, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(484, 'atropa belladonna and opium', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAOI) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'darunavir 600 mg', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(484, 'meperidine hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of DEMEROL Tablets or Oral Solution and/or precipitate withdrawal symptoms.', 'DailyMed'),
(484, 'remifentanil hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'butalbital, acetaminophen, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'fentanyl transdermal', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'tramadol hcl', 'N/A', 'severe', 'Drug Interactions Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse e', 'DailyMed'),
(484, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'hydrocodone bitartrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'levorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(484, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(484, 'oxycodone hydrochloride oral solution', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone) monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'hydrocodone bitartrate and ibuprofen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine,metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome (see PRECAUTIONS: Information for Patients ).', 'DailyMed'),
(484, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(484, 'buprenorphine sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'buprenorphine sublingual c-iii', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'ondansetron hcl', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(484, 'venlafaxine hcl', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'cyclobenzaprine hcl', 'N/A', 'severe', 'Drug Interactions Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(484, 'oliceridine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs,) serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'tramadol hcl er', 'N/A', 'major', 'Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.', 'DailyMed'),
(484, 'venlafaxine hcl er', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(484, 'cyclobenzaprine hcl er', 'N/A', 'severe', 'Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release capsules may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(484, 'alprazolam c-iv', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(484, 'butorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; INFORMATION FOR PATIENTS ].', 'DailyMed'),
(484, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(484, 'oxycodone hydrochloride and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(484, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(484, 'atazanavir and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.', 'DailyMed'),
(484, 'cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(484, 'safinamide mesylate', 'N/A', 'contraindicated', '7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2)].', 'DailyMed'),
(484, 'pentazocine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(484, 'methadone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(484, 'lenacapavir sodium', 'N/A', 'minor', 'Tramadol  tramadol A decrease in dose may be needed for tramadol with concomitant use.', 'DailyMed'),
(484, 'tramadol hcl and acetaminophen', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 includes clinically significant interactions with tramadol hydrochloride and acetaminophen tablets. Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride and Acetaminophen Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride and acetaminophen tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride and acetaminophen tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had deve', 'DailyMed'),
(481, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(481, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(481, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(481, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(481, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(481, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(481, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(481, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(481, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(481, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(481, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(481, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(481, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(481, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(481, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(481, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(481, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(481, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(481, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(481, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(481, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(481, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(481, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(481, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(481, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(481, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(481, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(481, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(481, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(481, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(481, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(481, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(481, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(481, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(481, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(481, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(481, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(481, 'selegiline hydrochloride', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)].', 'DailyMed'),
(481, 'ondansetron tablets', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(481, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(481, 'methadone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(481, 'fentanyl citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'sufentanil citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'oxycodone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'sumatriptan succinate, ondansetron', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(481, 'buprenorphine hydrochloride and naloxone hydrochloride dihydrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'ritonavir 100 mg', 'N/A', 'minor', 'Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(481, 'nalbuphine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients ].', 'DailyMed'),
(481, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(481, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(481, 'darunavir', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(481, 'buprenorphine and naloxone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'tapentadol hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'codeine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'protriptyline hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking ULTRAM (tramadol hydrochloride).', 'DailyMed'),
(481, 'sufentanil', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (e.g., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'oxycodone hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'darunavir ethanolate and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(481, 'venlafaxine hydrochloride, extended release', 'N/A', 'minor', '(7.10) Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St.', 'DailyMed'),
(481, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(481, 'atropa belladonna and opium', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAOI) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'darunavir 600 mg', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(481, 'meperidine hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of DEMEROL Tablets or Oral Solution and/or precipitate withdrawal symptoms.', 'DailyMed'),
(481, 'remifentanil hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'butalbital, acetaminophen, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'fentanyl transdermal', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'tramadol hcl', 'N/A', 'severe', 'Drug Interactions Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse e', 'DailyMed'),
(481, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'hydrocodone bitartrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'levorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(481, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(481, 'oxycodone hydrochloride oral solution', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone) monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'hydrocodone bitartrate and ibuprofen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine,metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome (see PRECAUTIONS: Information for Patients ).', 'DailyMed'),
(481, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(481, 'buprenorphine sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'buprenorphine sublingual c-iii', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'ondansetron hcl', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(481, 'venlafaxine hcl', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(481, 'cyclobenzaprine hcl', 'N/A', 'severe', 'Drug Interactions Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(481, 'oliceridine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs,) serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'tramadol hcl er', 'N/A', 'major', 'Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.', 'DailyMed'),
(481, 'venlafaxine hcl er', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(481, 'cyclobenzaprine hcl er', 'N/A', 'severe', 'Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release capsules may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(481, 'alprazolam c-iv', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(481, 'butorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; INFORMATION FOR PATIENTS ].', 'DailyMed'),
(481, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(481, 'oxycodone hydrochloride and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(481, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(481, 'atazanavir and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.', 'DailyMed'),
(481, 'cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(481, 'safinamide mesylate', 'N/A', 'contraindicated', '7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2)].', 'DailyMed'),
(481, 'pentazocine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(481, 'methadone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(481, 'lenacapavir sodium', 'N/A', 'minor', 'Tramadol  tramadol A decrease in dose may be needed for tramadol with concomitant use.', 'DailyMed'),
(481, 'tramadol hcl and acetaminophen', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 includes clinically significant interactions with tramadol hydrochloride and acetaminophen tablets. Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride and Acetaminophen Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride and acetaminophen tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride and acetaminophen tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had deve', 'DailyMed'),
(28390, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(28390, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(28390, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(28390, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(28390, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(28390, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(28390, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(28390, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(28390, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(28390, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(28390, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(28390, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28390, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(28390, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28390, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28390, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28390, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(28390, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28390, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28390, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(28390, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28390, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(28390, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(28390, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(28390, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(28390, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(28390, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(28390, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28390, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28390, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(28390, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(28390, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(28390, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(28390, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28390, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(28390, 'tranylcypromine', 'N/A', 'contraindicated', 'E [S ee Warnings and Precautions (5.5)]; f [S ee Warnings and Precautions (5.14)]; g [S ee Overdosage (10.1)] Table 4: Clinically Significant Drug Interactions with Individual Products* P r oduct C linical Comment on Concomitant Usea P r e dominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzaprine Contraindicateda SS Dextromethorphan Contraindicateda SS; Psychosis, bizarre behavior Dopamine Contraindicateda HR Droperidol Use with cautiond QT interval prolongation Entacapone Use with cautiond HR Fentanyl Use with cautiond SS Hydroxytryptophan Contraindicateda SS Levodopa Contraindicate', 'DailyMed'),
(28390, 'selegiline hydrochloride', 'N/A', 'contraindicated', '7 DRUG INTERACTIONS 7.1 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs with ZELAPAR is contraindicated [see Contraindications (4) and Warnings and Precautions (5.2)].', 'DailyMed'),
(28390, 'ondansetron tablets', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(28390, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28390, 'methadone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28390, 'fentanyl citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'sufentanil citrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'oxycodone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'sumatriptan succinate, ondansetron', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron tablets may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(28390, 'buprenorphine hydrochloride and naloxone hydrochloride dihydrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'ritonavir 100 mg', 'N/A', 'minor', 'Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(28390, 'nalbuphine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients ].', 'DailyMed'),
(28390, 'tranylcypromine sulfate', 'N/A', 'contraindicated', 'A [See Contraindications (4.1)]; b [See Warnings and Precautions (5.3)]; c [See Warnings and Precautions (5.7)] dIf not otherwise specified in this table, consider avoiding concomitant use (see also information on medication-free intervals, use agent at the lowest appropriate dose, monitor for effects of the interaction, advise the patient to report potential effects, and be prepared to discontinue the agent and treat effects of the interaction e [See Warnings and Precautions (5.5)] Product Clinical Comment on Concomitant Usea Predominant Effect/Risk [Hypertensive Reaction (HR)b or Serotonin Syndrome (SS)c] Altretamine Use with cautiond Orthostatic hypotensione Buspirone Contraindicateda HR Carbamazepine Contraindicateda SS Chlorpromazine Use with cautiond Hypotensive effectse Cyclobenzapr', 'DailyMed'),
(28390, 'dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate', 'N/A', 'minor', 'Examples selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28390, 'darunavir', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28390, 'buprenorphine and naloxone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'tapentadol hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'codeine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'protriptyline hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking ULTRAM (tramadol hydrochloride).', 'DailyMed'),
(28390, 'sufentanil', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (e.g., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'oxycodone hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed');

INSERT INTO drug_interactions (med_id, interaction_drug_name, interaction_dailymed_id, severity, description, source) VALUES
(28390, 'darunavir ethanolate and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28390, 'venlafaxine hydrochloride, extended release', 'N/A', 'minor', '(7.10) Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St.', 'DailyMed'),
(28390, 'desvenlafaxine er', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(28390, 'atropa belladonna and opium', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAOI) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'darunavir 600 mg', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28390, 'meperidine hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (MAOIs) (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of DEMEROL Tablets or Oral Solution and/or precipitate withdrawal symptoms.', 'DailyMed'),
(28390, 'remifentanil hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'hydrocodone bitartrate and aspirin', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'butalbital, acetaminophen, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'fentanyl transdermal', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'tramadol hcl', 'N/A', 'severe', 'Drug Interactions Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse e', 'DailyMed'),
(28390, 'butalbital, aspirin, caffeine and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'hydrocodone bitartrate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'levorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(28390, 'darunavir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28390, 'oxycodone hydrochloride oral solution', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone) monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'hydrocodone bitartrate and ibuprofen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine,metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome (see PRECAUTIONS: Information for Patients ).', 'DailyMed'),
(28390, 'trazodone hcl', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(28390, 'buprenorphine sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'buprenorphine sublingual c-iii', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'ondansetron hcl', 'N/A', 'moderate', '7.3 Tramadol Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. Monitor patients to ensure adequate pain control when ondansetron is administered with tramadol.', 'DailyMed'),
(28390, 'venlafaxine hcl', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'cyclobenzaprine hcl', 'N/A', 'severe', 'Drug Interactions Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(28390, 'oliceridine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs,) serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'tramadol hcl er', 'N/A', 'major', 'Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol.', 'DailyMed'),
(28390, 'venlafaxine hcl er', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of venlafaxine hydrochloride extended-release capsules and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release capsules are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(28390, 'cyclobenzaprine hcl er', 'N/A', 'severe', 'Based on its structural similarity to tricyclic antidepressants, cyclobenzaprine hydrochloride extended-release capsules may have life-threatening interactions with MAO inhibitors [SEE CONTRAINDICATIONS (4)], may enhance the effects of alcohol, barbiturates, and other CNS depressants, may enhance the seizure risk in patients taking tramadol, or may block the antihypertensive action of guanethidine and similarly acting compounds. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors [SEE WARNINGS AND PRECAUTIONS (5.1)].', 'DailyMed'),
(28390, 'alprazolam c-iv', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(28390, 'butorphanol tartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; INFORMATION FOR PATIENTS ].', 'DailyMed'),
(28390, 'elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28390, 'oxycodone hydrochloride and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers].', 'DailyMed'),
(28390, 'dextroamphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(28390, 'atazanavir and cobicistat', 'N/A', 'minor', 'Tramadol  tramadol When EVOTAZ is coadministered with tramadol, a decreased dose of tramadol may be needed.', 'DailyMed'),
(28390, 'cobicistat', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(28390, 'safinamide mesylate', 'N/A', 'contraindicated', '7.2 Opioid Drugs Because serious, sometimes fatal reactions have been precipitated with concomitant use of opioid drugs (e.g., meperidine and its derivatives, methadone, propoxyphene, or tramadol) and MAOIs, including selective MAO-B inhibitors, concomitant use of these drugs is contraindicated [see Warnings and Precautions (5.2)].', 'DailyMed'),
(28390, 'pentazocine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(28390, 'methadone', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(28390, 'lenacapavir sodium', 'N/A', 'minor', 'Tramadol  tramadol A decrease in dose may be needed for tramadol with concomitant use.', 'DailyMed'),
(28390, 'tramadol hcl and acetaminophen', 'N/A', 'major', '7 DRUG INTERACTIONS Table 2 includes clinically significant interactions with tramadol hydrochloride and acetaminophen tablets. Table 2: Clinically Significant Drug Interactions with Tramadol Hydrochloride and Acetaminophen Tablets Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride and acetaminophen tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride and acetaminophen tablets is achieved. Since M1 is a more potent -opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had deve', 'DailyMed'),
(27880, 'tramadol hydrochloride', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(27880, 'fluvoxamine maleate', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors See WARNINGS Serotonergic Drugs Based on the mechanism of action of fluvoxamine and the potential for serotonin syndrome, caution is advised when fluvoxamine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'carbamazepine', 'N/A', 'minor', 'Carbamazepine causes, or would be expected to cause, decreased levels of the following:acetaminophen, alprazolam, dihydropyridine calcium channel blockers (e.g., felodipine), cyclosporine, corticosteroids (e.g., prednisolone, dexamethasone), clonazepam, clozapine, dicumarol, doxycycline, ethosuximide, haloperidol, itraconazole, lamotrigine, levothyroxine, methadone, methsuximide, midazolam, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, phensuximide, phenytoin, praziquantel, protease inhibitors, risperidone, theophylline, tiagabine, topiramate, tramadol, tricyclic antidepressants (e.g., imipramine, amitriptyline, nortriptyline), valproate, warfarin, ziprasidone, zonisamide.', 'DailyMed'),
(27880, 'venlafaxine hydrochloride', 'N/A', 'moderate', '(7.10)Serotonergic drugs (e.g., triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Serotonergic Drugs Based on the mechanism of action of Venlafaxine Extended Release Tablets and the potential for serotonin syndrome, caution is advised when Venlafaxine Extended Release Tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'sertraline hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for serotonin syndrome, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'citalopram hydrobromide', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram hydrobromide is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'citalopram', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs including Citalopram HBr, and the potential for serotonin syndrome, caution is advised when Citalopram HBr is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'escitalopram oxalate', 'N/A', 'moderate', '7 DRUG INTERACTIONS 7.1 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs including Lexapro, and the potential for serotonin syndrome, caution is advised when Lexapro is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'fluoxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'duloxetine hydrochloride', 'N/A', 'moderate', '7.14 Serotonergic DrugsBased on the mechanism of action of SNRIs and SSRIs, including Cymbalta, and the potential for serotonin syndrome, caution is advised when Cymbalta is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'warfarin sodium', 'N/A', 'minor', 'Acetaminophenalcoholallopurinolaminosalicylic acidamiodarone HClargatrobanaspirinatenololatorvastatinazithromycinbivalirudincapecitabinecefamandolecefazolincefoperazonecefotetancefoxitinceftriaxonecelecoxibcerivastatinchenodiolchloramphenicolchloral hydratechlorpropamidecholestyraminecimetidineciprofloxacincisaprideclarithromycinclofibratecyclophosphamidedanazoldextrandextrothyroxinediazoxide diclofenacdicumaroldiflunisaldisulfiramdoxycyclineerythromycinesomeprazoleethacrynic acidezetimibefenofibratefenoprofenfluconazolefluorouracilfluoxetineflutamidefluvastatinfluvoxaminegefitinibgemifibrozilglucagonhalothaneheparinibuprofenifosfamideindomethacininfluenza virus vaccineitraconazoleketoprofenketorolaclansoprazolelepirudinlevamisolelevofloxacinlevothyroxineliothyronine lovastatinmefenam', 'DailyMed'),
(27880, 'fluoxetine', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'paroxetine hydrochloride', 'N/A', 'moderate', 'Serotonergic Drugs: Based on the mechanism of action of paroxetine hydrochloride and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'cyclobenzaprine hydrochloride', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. ________________________ ULTRAM (tramadol HCl tablets, Ortho-McNeil Pharmaceutical) ULTRACET (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(27880, 'tramadol hydrochloride and acetaminophen', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(27880, 'fluoxetine capsules', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'ondansetron hydrochloride', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(27880, 'tramadol hydrochloride, gaba', 'N/A', 'severe', 'Drug Interactions CYP2D6 and CYP3A4 Inhibitors Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see CLINICAL PHARMACOLOGY, Pharmacokinetics), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including seizures and serotonin syndrome. Serotonergic Drugs There have been postmarketing reports of serotonin syndrome with use of tramadol and SSRIs/SNRIs or MAOIs and 2-adrenergic blockers. Caution is advised when tramadol hydrochloride is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible no', 'DailyMed'),
(27880, 'cyclobenzaprine hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.', 'DailyMed'),
(27880, 'citalopram hydrobromide, choline', 'N/A', 'moderate', 'Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including citalopram, and the potential for serotonin syndrome, caution is advised when citalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'tramadol hydrochloride, .gamma.-aminobutyric acid', 'N/A', 'minor', 'Drug Interactions In vitro studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.', 'DailyMed'),
(27880, 'fluoxetine hydrochloride, choline', 'N/A', 'moderate', '7.3 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including fluoxetine, and the potential for serotonin syndrome, caution is advised when fluoxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'ondansetron', 'N/A', 'minor', 'However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P-388 mouse leukemia model is not affected by ondansetron.', 'DailyMed'),
(27880, 'mirtazapine', 'N/A', 'moderate', 'Monoamine Oxidase Inhibitors (See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.) Serotonergic Drugs Based on the mechanism of action of mirtazapine and the potential for serotonin syndrome, caution is advised when mirtazapine tablets are coadministered with other drugs or agents that may affect the serotonergic neurotransmitter systems, such as tryptophan, triptans, linezolid, serotonin reuptake inhibitors, venlafaxine, lithium, tramadol, or St.', 'DailyMed'),
(27880, 'escitalopram', 'N/A', 'moderate', '7.1 Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs including escitalopram, and the potential for serotonin syndrome, caution is advised when escitalopram is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'paroxetine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St.', 'DailyMed'),
(27880, 'buprenorphine hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs),, triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(27880, 'venlafaxine', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including venlafaxine hydrochloride, and the potential for serotonin syndrome, caution is advised when venlafaxine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(27880, 'buprenorphine hydrochloride and naloxone hydrochloride', 'N/A', 'minor', '7.4 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(27880, 'oxymorphone hydrochloride', 'N/A', 'minor', '7.3 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(27880, 'hydrocodone bitartrate and acetaminophen', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(27880, 'cyclobenzaprine', 'N/A', 'minor', '(See CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.  ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)  ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)', 'DailyMed'),
(27880, 'hydromorphone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'buprenorphine', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'buprenorphine hydrochloride sublingual', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'oxycodone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'dextroamphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(27880, 'buprenorphine hydrochloride, naloxone hydrochloride', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'morphine sulfate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'sertraline', 'N/A', 'minor', 'Examples: other SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(27880, 'acetaminophen and codeine phosphate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(27880, 'pentazocine and naloxone', 'N/A', 'minor', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome.', 'DailyMed'),
(27880, 'buprenorphine hcl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'paroxetine hydrochloride hemihydrate', 'N/A', 'moderate', 'Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St.', 'DailyMed'),
(27880, 'desvenlafaxine succinate', 'N/A', 'minor', 'Examples other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(27880, 'ritonavir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic:tramadol, propoxyphene,methadone,fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(27880, 'trazodone hydrochloride', 'N/A', 'minor', 'Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St.', 'DailyMed'),
(27880, 'oxycodone and acetaminophen', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tryptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue), has resulted in serotonin syndrome [see PRECAUTIONS; Information for Patients/Caregivers ].', 'DailyMed'),
(27880, 'desvenlafaxine', 'N/A', 'minor', 'Examples Other SNRIs, SSRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, and St.', 'DailyMed'),
(27880, 'metaxalone', 'N/A', 'minor', 'Examples of serotonergic drugs include: selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(27880, 'amphetamine', 'N/A', 'minor', 'Examples of serotonergic drugs include selective serotonin reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St.', 'DailyMed'),
(27880, 'norvir', 'N/A', 'minor', 'Other Agents Analgesics, Narcotic: tramadol, propoxyphene, methadone, fentanyl  analgesics  methadone  fentanyl A dose decrease may be needed for these drugs when co-administered with ritonavir.', 'DailyMed'),
(27880, 'butalbital, aspirin, cafeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'butalbital, acetaminophen, caffeine, and codeine phosphate', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'acetaminophen, caffeine, dihydrocodeine bitartrate', 'N/A', 'moderate', 'Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and monoamine oxidase (MAO) inhibitors (used to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) [see PRECAUTIONS; Information for Patients].', 'DailyMed'),
(27880, 'benzhydrocodone and acetaminophen', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e.', 'DailyMed'),
(27880, 'fentanyl', 'N/A', 'minor', 'Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).', 'DailyMed'),
(27880, 'triazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorphanol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed'),
(27880, 'elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate', 'N/A', 'minor', 'Tramadol  tramadol A dose decrease may be needed for tramadol with concomitant use.', 'DailyMed'),
(27880, 'alprazolam', 'N/A', 'minor', 'Examples Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.', 'DailyMed');

